CA1040082B - Process for the demonstration and determination of reaction components having specific binding affinity for each other - Google Patents
Process for the demonstration and determination of reaction components having specific binding affinity for each otherInfo
- Publication number
- CA1040082B CA1040082B CA303,100A CA303100A CA1040082B CA 1040082 B CA1040082 B CA 1040082B CA 303100 A CA303100 A CA 303100A CA 1040082 B CA1040082 B CA 1040082B
- Authority
- CA
- Canada
- Prior art keywords
- component
- determined
- binding partner
- binding
- coupling product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
- Y10S436/818—Human chorionic gonadotropin
Abstract
ABSTRACT OF THE DISCLOSURE
The disclosure describes a process for the demonstra-tion and determination of a component of the reaction between a bindable substance which is an antigen, a hapten, or a low molecular substance, and a protein capable of binding the bindable substance specifically. The protein can be an antibody or a specific binding protein. The process involves the steps providing a given quantity of binding partner of the component to be determined in a soluble or insoluble form, reacting the component to be determined with its binding partner, and when the binding partner is in soluble form, adding a given quantity of an antibody against the binding partner, the antibody being in insoluble form. The solid phase is separated from the liquid phase and to the solid phase there is added a coupling product of the component to be determined with an enzyme. The coupling product may also be obtained by binding to an enzyme a substance capable of reacting specifically with the component to be determined or its binding partner. The coupling product is used in quantity at least sufficient to react with all of the binding partner of the component to be determined. Finally, the enzyme activity of the liquid or solid phase of the reaction mixture obtained is determined. Test packs for the performance of this process are also described. This enables to demonstrate or determine substances occurring in extremely low concentra-tions in, for example, serum or urine.
The disclosure describes a process for the demonstra-tion and determination of a component of the reaction between a bindable substance which is an antigen, a hapten, or a low molecular substance, and a protein capable of binding the bindable substance specifically. The protein can be an antibody or a specific binding protein. The process involves the steps providing a given quantity of binding partner of the component to be determined in a soluble or insoluble form, reacting the component to be determined with its binding partner, and when the binding partner is in soluble form, adding a given quantity of an antibody against the binding partner, the antibody being in insoluble form. The solid phase is separated from the liquid phase and to the solid phase there is added a coupling product of the component to be determined with an enzyme. The coupling product may also be obtained by binding to an enzyme a substance capable of reacting specifically with the component to be determined or its binding partner. The coupling product is used in quantity at least sufficient to react with all of the binding partner of the component to be determined. Finally, the enzyme activity of the liquid or solid phase of the reaction mixture obtained is determined. Test packs for the performance of this process are also described. This enables to demonstrate or determine substances occurring in extremely low concentra-tions in, for example, serum or urine.
Description
~,q~ Z
For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances.
Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specific-ally. As e~amples of such combinations are mentioned cortisol and transcortin, 17~-oestradiol and the oestradiol-binding receptor protein of the uterus.
It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.
; Migh molecular substances, such as simple and con-~ugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.
Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be deterrnined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature depend upon the nature of the specific bind-ing protein. They speak of "competitive protein binding assays", where receptor or transport proteins are used, and of "radioimmunological determinations" where antibodies are employed as specific binding protein.
Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance.
Where use is made of the binding affinity between a low mole_ular substance and its specific binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventlonal in radioimmuno-logical methods.
For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances parti-cipating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.
In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low ~oncentrations z in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containiny antisubstances with an extremely high binding affinity for ACTH.
Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.
Although, in principle, the immunological cross-reaction between HCG and LH enables both hormones to be deter-mined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems ~s insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium.
These methods, however, are very laborious, and the results often unsatisfactory.
A process has now been found for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low mole-ular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein. According to one embodiment, the process com-prises: a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form, b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid U~18Z
phase and a liquid phase, c) separating the solid phase from the liquid phase, d) adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme, which quantity of coupling product is at least suffi-cient to react with all of the binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
ccording to another embodiment, the process comprises:
a) providing a given quantity of the binding partner of the com-ponent to be determined in a soluble form; b) reacting the com-ponent to be determined with its binding partner; c) adding a given quantity of an antibody against said binding partner, which antibody is in an.insoluble form, to form a reaction mixture having a solid phase and a liquid phase; d) separating the solid phase frorn the liquid phase; e) adding to said solid phase a given quantity of a coupling product of the component to ~e determined with an enzyme, which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (c) of the insolubilised antibody against saidbinding partner; and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
According to another embodiment, the process comprises:
a) providing a given quantity of the binding partner of the com-ponent to be determined, which binding partner is in an insoluble form; b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase; c) separating the solid phase from the liquid phase; d) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step (b) , which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (a), of the insolubilised binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined. Preferably, the coupling product is obtained by binding to an enzyme the binding partner of the component to be determined. Preferably also, the quantity, provided in step (a), of the binding partner of the component to be determined is at least sufficient to react with all of the component to be determined.
According to another embodiment, the process comprises the steps of: a) providing a given quantity of the binding partner of the component to be determined in a soluble form b) reacting the component to be determined with its binding partner, c) adding a given quantity of antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase d) separatinc~ the solid phase from the liquid phase, e) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of react-ing specifically with one of the reactants of step (b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (c), of the in-solubilised antibody against said binding partner' and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined. Preferably, the coupling product is obtained by binding to an enzyme the binding partner of the component to be de-termined. Preferably also, the quantity, provided in step (a), of the binding partner of the component to be determined is at least sufficient to react with ~040(~f~Z
all of the component to be determined, and the quantity, provided in step (c), of the insolubilised antibody against said binding partner, is at least sufficient to react with all of said binding partner.
The binding partner required for the determination of the component present in an unknown quantity is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an in-soluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding anti-substances against it.
The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.
The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten/antibody anda low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an anti-body against ~e gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.
The essence of the method is the performance in two steps,in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.
- ~4~Z
The most important advantages of the method found are:
1) the first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods. 2) In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Especially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.
The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of blood-clotting, fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibod.ies can be determined in this manner.
The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH required for the immunochemical reaction, viz. between S and 9, by adding a dry buffer salt or a small volume of a con-centrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction.
For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.
The manufacture of the insolubilised reaction com-ponent can take place in various manners, i.e. dependent upon the properties of this reaction component. Thus, antibodies, ~k~ Z
specific binding proteins and protein-like antigen can be in-solubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative pro-tein coupled with an insoluble carrier. Low molecular substan-ces can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.
The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be introduced by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.
The choice of the enzyme tha-t is to form a part of the coupling product is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme \
~C3 4~ 3Z
catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.
According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophoto-metrically or fluorimetrically. These determinations can also be automated.
In the manufacture of the coupling products enzymes such as catalase, peroxidase, ~-glucuronidase, ~-B-glucosidase, ~-D-galactosidase, urease, glucose-oxidase and galactose-oxidase are preferred, especially the group of the oxidoreductases.
The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be deter-mined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors.
In order to enable the reaction to be performed in the hetero-geneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centri-fugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged.
Separation by filtration and decantation is also possible.
The second part of the determination is performed by resuspending the insoluble substance, which forms the solid Z
phase, preferably in a buffer, and to react it with a certain quantity of a coupling product of the substance to be determined with an enzyme, for example, peroxidase. After a certain time the solid phase is separated again, for example by centrifugation, after which the enzyme activity in the liquid phase is determined.
This enzyme activity is a measure for the quantity of substance to be determined in the test liquid. The second part of the determination can also be performed by reacting the insoluble substance from the first part of the determination, with a coupling product obtained by binding a third substance capable of reacting specifically with the reaction component to be determined, with an enzyme. This will be the case when an antibody is determined by the insolubilised corresponding anti-gen in the first part of the determination, and a second anti-body, against the first, which is coupled with an enzyme, is used in the second part of the determination.
The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a sub-strate and other substances required for the relative enzyme reaction.
Pre~erably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.
The form in which the reagents can be used are manifold.
The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.
The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.
For the performance of the process according to the invention a test pack is usually employed.
In accordance with the invention there is provided a test pack comprising: a) a given quantity of an insoluble form of the binding partner of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised binding partner of the component to be determined and c) a substrate for the determination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack comprising: a) an insoluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolubilised binding partner of the com-ponent to be determined, and c) a substrate for the deter-mination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack, comprising: a) a given quantity of a soluble form of the binding partner of the component to be determined, b) a given quantity of an insoluble form of an antibody against said binding partner, c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolubilised antibody against said binding partner' and d) a substrate for the determination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack comprising: a) a soluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined, b) an insoluble form of an antibody against said binding partner, in a quantity at least sufficient to react with all of said binding partner' c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling prod-uct is at least immunochemically equivalent to the quantity of the insolubilised antibody against said binding partner' and d) a substrate for the determination of enzyme activity of said coupling product.
The invention is further illustrated by the follow-ing examples, which are on no account intended to limit the invention.
Example I
Determination o:E human chorionic gonadotrophin (HCG) in serum.
a) Preparation of HCG-HRP.
Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH
. - 12 -o~
6.2. After 40 ~/ltr of 25% glutaric aldehyde solution had been added, the mixture was shaken at room temperature for two hours.
Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex* G-200 in 0.05 M
phosphate buffer of pH 6.2. l'he fractions whose highest per-centage of enzyme activity was bound by antibodies against HCG, were used in the test system.
b) Preparation of antibodies against HCG.
Antibodies against HCG were generated in rabbits as described by Schuurs et al. in Acta Endocr. (Kbh.) 59, 120 (1968).
c) Preparation of the immuno-adsorbent, anti-HCG-cellulose.
The y-globulin fraction of the anti-HCG-serum described under b) was prepared by precipitation with 18%
(w/v) solid Na2S04. The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml.
M-~minobenzyloxy methyl cellulose (350 mg) prepared by Gurvich's method, described in Biokhimiya 26, 934 (1961), was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36% hydrochloric acid and, dropwise, 10 ml of 10%
NaNO2-solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6. Of the y-globulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4C, centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH 6Ø
d) Determination of HCG in serum.
A dilution series of HCG (8-4-2-1-0.5-0.25-0 I.U./ml) was prepared with a dilution liquid consisting of one part of * trademark Z
man's serum and 2 parts of 0.05 M phosphate buffer of pM 6.2.
Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immuno-adsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH
6.2, and rotated again at room temperature for 2 hours.
After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of lO ~l of 30% H202 and 20 mg of 5-amino salicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6Ø After 30 minutes the extinction was measured at 460 nm.
In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of l I.U./ml caused the maximum increase. In this tes-t the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enæyme activity, i.e. owing to turbidity of the serum and the peroxidase-like activity of it.
The ~ICG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.
EXAMPLE II
Determination o~ HCG in low concentrations by means of an enzyme/
antigen coupling product.
a) Preparation of antisubstances against rabbit-y-globulin~
Rabbit-y-globulin was isolated from normal rabbit serum by precipitating it with 18% (w/v) solid Na2S04. Anti-bodies against it were generated in a sheep. The injection scheme was:
1(~4(~ 32 _ . ;. _ . _ Day Quant1ty Freund's adjuvant Manner of injection . . . ......... _ 00.5 mg ~ Intramuscularly 140.5 mg +
281 mg + ll 421 mg _ Intravenously 561 mg _ _ On day 70 the sheep was exsanguinated.
b) Preparation of [sheep-anti-(rabbit-y-globulin)]-cellulose.
The y-globulin fraction of the sheep serum described under a) was prepared by precipitating it with 16% (w/v) solid sodium sulphate. This Y-globulin fraction was bound to m-aminobenzyloxymethyl-cellulose, as described in Example I c).
c) Determination of human chorionic gonadotrophin (HCG).
A dilution series of HCG was prepared in 0.01 M phos-phate buffer of pH 6.0, which also contained 2% (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./l, the dilution factor being 2.
To 5 ml of HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see Example I b)), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature Eor 30 minutes, after which 1.5 mg of (sheep-anti~rabbit-y-globulin)]-cellulose were added and the mixture was rotated for 2 hours.
The cellulose was centrifuged for 10 minutes at 3000 r.p.m. and resuspended in 1 ml of a solution of HCG-HRP coupling product, prepared in accordance with Example I a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2% normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of enzyme substrate consisting of 10 ~1 of 30% H202 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of ~L~)9LU~1~2 pH 6Ø The mixture was left to stand for 30 minutes at 25~, after which the extinction was measured at 460 nm. In the supernatant liquid 100% enzyme activity is measured provided that no anti-HCG serum is added to the system.
A dilution series of HCG, prepared with children's - urine as dilution liquid, gave an identical pattern so that also measurings in urine samples can be performed.
The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.
Example III
Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.
a) Preparatlon of the immuno-adsorbent HCG cellulose.
This immuno-adsorbent was prepared by the method mentioned in Example I c), but instead of rabbit-y-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.
b) Purification of antibodies against HCG.
Ten ml of rabbit-anti-HCG serum, prepared in accordance with Example I b), was dilutecl with 90 ml of 0.05 M citrate of pH
5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex*G-25. The immuno-adsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2Ø The fractions were collected in one-half volume of 0.25 M NaHC03, tested for their content of antibodies and protein, and the suitable fractions were frozen.
c) Preparation of the coupling product (anti-HCG)-HRP.
Twenty mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 ~1 of 25%
glutaric aldehyde solution, after which the mixture was shaken * trademark ~ z for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex*G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.
d) Determination of HCG and LH.
Ten ml of a HCG dilution series of HCG and 10 ml of a HCG dilution series of LH were mixed with 5 mg of anti-HCG
cellulose, prepared in accordance with Example I c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures rotated at room temperature for 2 hours. The immuno-adsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6Ø
To the immuno-adsorbent 1 ml of the (anti-HCG)-HRP
coupling product was added in the desired dilution, after which the mixture was rotated again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.
By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per litre respectively could be deterrnined. I~ the centrifugation step is omitted the optimum sample size is 0.5 ml and the sensitivity about 100 I.U. of HCG
per litre, or about 200 I.U. of LH per litre, so that the method ac~ording to the invention yields a 10-20 fold increase in sensitivity.
Example IV
Determination of HCG and anti-HCG.
a) Rabbit-serum was fractionated over DEAE cellulose in accord-ance with the prescription of H.A. Sober and others in J. Am.
Chem. Soc. 78, 756 (1956).
The isolated y-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating * trademark l~(lVl3Z
antibodies in a sheep in accordance with the scheme of Example II a), while besides 100 mg of rabbit-Y-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in Example I c).
From the sheep [anti-(rabbit-y-globulin)] serum prepared the specific antibodies were isolated by -the method described in Example III b) with the immuno-adsorbent prepared.
b) The coupling product [anti-(rabbit-y-globulin)]-HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in Example III c).
c) Determination of anti-HCG.
A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6Ø
Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see Example III a)). The re-action mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b). The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in Example I d).
d) Determination of HCG.
With the reagents prepared, HCG was determined by in-cubating solutions of it with 0.5 ml of rabbit-(anti-HCG) serum in a dilution which in the system described under c) just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under c) with the mixture obtained.
Where use was made of 5 ml of HCG solution, it proved to be possible to demonstrate concentrations of about 10 I.U./l of HCG.
Example V
Determination of insulin in serum.
a) Preparation of insulin-~glucose-oxidase).
Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5.
To this solution 5 ~1 of 25% glutaraldehyde solution were added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex*G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose high-est percentage of enzyme activity could be bound by antibodiesagainst insulin were used in the test system.
b) Preparation of antibodies against insulin.
Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freund's adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.
c) Preparation of anti-substances against cavia y-globulin.
Cavia y-globulin was prepared by adding one volume of a saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33%
saturated (NH4)2S04 solution and then taken up in a physiologic-al salt solution. A sheep was immunized with increasing dosages - of the y-globulin prepared, viz. 0, 5, 1 and 2 mg. The inject-ions were given every 2 weeks, the immunogen being mixed with complete Freund's adjuvant. Two weeks after the last injection another 2 mg of y-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.
d) Preparation of insoluble antibodies against cavia y-globulin.
* trademark Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5% (w/v) CNBr solution, after which the pH was adjusted to 10.5 with an 1 N NaOH-solution, and it was maintained at it for two minutes.
The cellulose was washed with ice water and with 0.1 M NaHC03.
To 10 ml of sheep-anti-(cavia y-globulin) serum 1.6 gm of NaS04 were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16%
(w/v) Na2504 solution, and finally taken up in 10 ml of 0.1 M
NaHC03.
The activated cellulose was mixed with 40 ml of a 0.1 M NaHC03 solution and the 10 ml of y-globulin solution. This suspension was rotated for 40 hours at 4C and washed, twice with 5 ml of 0.5 M NaHC03, twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH
6.2.
e) Determination of insulin in serum.
Four ml of an insulin dilution series in the range of from 0-100 ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml of anti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immuno-adsorbent prepared under d), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2% sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immuno-adsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained 50 mg of glucose, 10 ~gm of peroxidase and 1 mg of 5-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6Ø
The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a 10-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.
Example VI
Determination of oestradiol.
a) Preparation of oestradiol-17-succinyl-HRP.
Fifty mg of oestradiol-17-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of dioxane. To the cold solution (2C) 15 ~1 of isobutylchlorocarbonate were added.
After 30 minutes this solution was mixed with 100 mg of horse-radish peroxidase (HRP) in 7.5 ml of a mixture of dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2C, after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by preci-pitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.
b) Preparation of oestradiol-17-succinyl-BSA.
The preparation was prepared by the mixed anhydride method as described under a). The starting material was 100 mg of oestradiol-17-haemisuccinate and 150 mg of bovine serum albumin (BSA).
~) Preparation of anti-substances against oestradiol.
A sheep was injected every 4 weeks with 4 mg of oestradiol-17-succinyl-BSA in complete Freund's adjuvant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA.
d) Preparation of anti-substances against sheep y-globulin.
Sheep y-globulin was prepared as described in Example II b), this time, however, with 16% w/v sodium sulphate. Rabbits were immunized with this sheep-y-globulin in accordance with the following scheme:
Day Quantity Freund's adjuvant~ Manner of injection ~ 0 200 ~gm + Intramuscularly 14 400 ~gm +
28 800 ~gm + ll 42 800 ~gm l Intravenously Two weeks after the last injection the animals were exsanguinated.
e) Preparation of the immuno-adsorbent [rabbit-anti-(sheep~ -globulin)] cellulose.
The ~-globulin fraction of the anti-sera described under b) was prepared by precipitation with 18% w/v Na2S04.
The product obtained was coupled with cellulose by Gurvich's method described in Example I c).
f) Determination of oestradiol.
A dilution series of oestradiol (0-0.5-1-2-4-8-16 ng/ml) was prepared in phosphate buffer of pH 6Ø Five ml of sample were mixed with 0.5 ml of the sheep-anti-oestradiol-serum in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immuno-adsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M
phosphate buffer of pH 6.0 containing 2% BSA. Then 1 ml of oestradiol-17-succinyl-HRP, diluted to the desired strength Z
wlth the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrlfuged again and the enzyme activity in the supernatant liquid was measured as described in Example I.
By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10, compared with the test without centrifugation step.
Example VII
Determination of cortisol.
a) Preparation of cortisol-21-galactose-oxidase.
Fifty mg of cortisol-21-haemisuccinate and 100 mg of galactoseoxidase were coupled by the mixed anhydride method as described in Example VI a).
b) Preparation of insoluble transcortine.
One hundred mg of transcortine purified by DEAE
cellulose chromatography, followed by hydroxylapatite chromato-graphy, were coupled with 3 gm of Sepharose* 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml o~ 2.5% (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose* was washed with ice-water and with 0.1 M NaHC03, after which 100 mg of transcortine in 20 ml of 0.1 M NaHCO3 were added, and the suspension was shaken at 4C for 24 hours.
After being washed successively with 0.5 M NaHCO3, 0.05 M
citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH
6.0, the Sepharose* was kept in -the last buffer, to which 0.1%
merthiolate had been added.
c) Determination of cortisol.
A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6Ø
* trademark ~ 23 -. _ ~u~z Five ml of each cortisol solution (in 0.05 M phosphate bufferof pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose*, at 4C. After centrifugation 1 ml of cortisol-21-galactose oxidase solution, diluted to a suitable _oncentra-tion in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4C. After re-centrifugation the enzyme activity in the supernatant liquid was determined by - adding 0.5 ml of it to 1.5 ml of substrate consisting of 100 mg of D-galactose, 20 mg of 5-aminosalicylic acid and 10 ~gm of peroxidase in 150 ml of 0.02 M phosphate buffer of pH 6Ø
Finally, after 30 minutes, the extinction was measured at 460 nm.
By this method about 1 ng/ml cortisol could be demon-strated, which means an increase in sensitivity by a factor 10.
* trademark : - 24 -
For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances.
Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specific-ally. As e~amples of such combinations are mentioned cortisol and transcortin, 17~-oestradiol and the oestradiol-binding receptor protein of the uterus.
It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.
; Migh molecular substances, such as simple and con-~ugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.
Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be deterrnined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature depend upon the nature of the specific bind-ing protein. They speak of "competitive protein binding assays", where receptor or transport proteins are used, and of "radioimmunological determinations" where antibodies are employed as specific binding protein.
Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance.
Where use is made of the binding affinity between a low mole_ular substance and its specific binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventlonal in radioimmuno-logical methods.
For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances parti-cipating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.
In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low ~oncentrations z in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containiny antisubstances with an extremely high binding affinity for ACTH.
Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.
Although, in principle, the immunological cross-reaction between HCG and LH enables both hormones to be deter-mined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems ~s insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium.
These methods, however, are very laborious, and the results often unsatisfactory.
A process has now been found for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low mole-ular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein. According to one embodiment, the process com-prises: a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form, b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid U~18Z
phase and a liquid phase, c) separating the solid phase from the liquid phase, d) adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme, which quantity of coupling product is at least suffi-cient to react with all of the binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
ccording to another embodiment, the process comprises:
a) providing a given quantity of the binding partner of the com-ponent to be determined in a soluble form; b) reacting the com-ponent to be determined with its binding partner; c) adding a given quantity of an antibody against said binding partner, which antibody is in an.insoluble form, to form a reaction mixture having a solid phase and a liquid phase; d) separating the solid phase frorn the liquid phase; e) adding to said solid phase a given quantity of a coupling product of the component to ~e determined with an enzyme, which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (c) of the insolubilised antibody against saidbinding partner; and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
According to another embodiment, the process comprises:
a) providing a given quantity of the binding partner of the com-ponent to be determined, which binding partner is in an insoluble form; b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase; c) separating the solid phase from the liquid phase; d) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step (b) , which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (a), of the insolubilised binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined. Preferably, the coupling product is obtained by binding to an enzyme the binding partner of the component to be determined. Preferably also, the quantity, provided in step (a), of the binding partner of the component to be determined is at least sufficient to react with all of the component to be determined.
According to another embodiment, the process comprises the steps of: a) providing a given quantity of the binding partner of the component to be determined in a soluble form b) reacting the component to be determined with its binding partner, c) adding a given quantity of antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase d) separatinc~ the solid phase from the liquid phase, e) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of react-ing specifically with one of the reactants of step (b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step (c), of the in-solubilised antibody against said binding partner' and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined. Preferably, the coupling product is obtained by binding to an enzyme the binding partner of the component to be de-termined. Preferably also, the quantity, provided in step (a), of the binding partner of the component to be determined is at least sufficient to react with ~040(~f~Z
all of the component to be determined, and the quantity, provided in step (c), of the insolubilised antibody against said binding partner, is at least sufficient to react with all of said binding partner.
The binding partner required for the determination of the component present in an unknown quantity is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an in-soluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding anti-substances against it.
The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.
The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten/antibody anda low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an anti-body against ~e gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.
The essence of the method is the performance in two steps,in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.
- ~4~Z
The most important advantages of the method found are:
1) the first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods. 2) In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Especially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.
The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of blood-clotting, fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibod.ies can be determined in this manner.
The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH required for the immunochemical reaction, viz. between S and 9, by adding a dry buffer salt or a small volume of a con-centrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction.
For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.
The manufacture of the insolubilised reaction com-ponent can take place in various manners, i.e. dependent upon the properties of this reaction component. Thus, antibodies, ~k~ Z
specific binding proteins and protein-like antigen can be in-solubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative pro-tein coupled with an insoluble carrier. Low molecular substan-ces can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.
The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be introduced by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.
The choice of the enzyme tha-t is to form a part of the coupling product is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme \
~C3 4~ 3Z
catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.
According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophoto-metrically or fluorimetrically. These determinations can also be automated.
In the manufacture of the coupling products enzymes such as catalase, peroxidase, ~-glucuronidase, ~-B-glucosidase, ~-D-galactosidase, urease, glucose-oxidase and galactose-oxidase are preferred, especially the group of the oxidoreductases.
The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be deter-mined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors.
In order to enable the reaction to be performed in the hetero-geneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centri-fugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged.
Separation by filtration and decantation is also possible.
The second part of the determination is performed by resuspending the insoluble substance, which forms the solid Z
phase, preferably in a buffer, and to react it with a certain quantity of a coupling product of the substance to be determined with an enzyme, for example, peroxidase. After a certain time the solid phase is separated again, for example by centrifugation, after which the enzyme activity in the liquid phase is determined.
This enzyme activity is a measure for the quantity of substance to be determined in the test liquid. The second part of the determination can also be performed by reacting the insoluble substance from the first part of the determination, with a coupling product obtained by binding a third substance capable of reacting specifically with the reaction component to be determined, with an enzyme. This will be the case when an antibody is determined by the insolubilised corresponding anti-gen in the first part of the determination, and a second anti-body, against the first, which is coupled with an enzyme, is used in the second part of the determination.
The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a sub-strate and other substances required for the relative enzyme reaction.
Pre~erably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.
The form in which the reagents can be used are manifold.
The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.
The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.
For the performance of the process according to the invention a test pack is usually employed.
In accordance with the invention there is provided a test pack comprising: a) a given quantity of an insoluble form of the binding partner of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised binding partner of the component to be determined and c) a substrate for the determination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack comprising: a) an insoluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolubilised binding partner of the com-ponent to be determined, and c) a substrate for the deter-mination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack, comprising: a) a given quantity of a soluble form of the binding partner of the component to be determined, b) a given quantity of an insoluble form of an antibody against said binding partner, c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolubilised antibody against said binding partner' and d) a substrate for the determination of enzyme activity of said coupling product.
According to another embodiment there is provided a test pack comprising: a) a soluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined, b) an insoluble form of an antibody against said binding partner, in a quantity at least sufficient to react with all of said binding partner' c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling prod-uct is at least immunochemically equivalent to the quantity of the insolubilised antibody against said binding partner' and d) a substrate for the determination of enzyme activity of said coupling product.
The invention is further illustrated by the follow-ing examples, which are on no account intended to limit the invention.
Example I
Determination o:E human chorionic gonadotrophin (HCG) in serum.
a) Preparation of HCG-HRP.
Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH
. - 12 -o~
6.2. After 40 ~/ltr of 25% glutaric aldehyde solution had been added, the mixture was shaken at room temperature for two hours.
Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex* G-200 in 0.05 M
phosphate buffer of pH 6.2. l'he fractions whose highest per-centage of enzyme activity was bound by antibodies against HCG, were used in the test system.
b) Preparation of antibodies against HCG.
Antibodies against HCG were generated in rabbits as described by Schuurs et al. in Acta Endocr. (Kbh.) 59, 120 (1968).
c) Preparation of the immuno-adsorbent, anti-HCG-cellulose.
The y-globulin fraction of the anti-HCG-serum described under b) was prepared by precipitation with 18%
(w/v) solid Na2S04. The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml.
M-~minobenzyloxy methyl cellulose (350 mg) prepared by Gurvich's method, described in Biokhimiya 26, 934 (1961), was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36% hydrochloric acid and, dropwise, 10 ml of 10%
NaNO2-solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6. Of the y-globulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4C, centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH 6Ø
d) Determination of HCG in serum.
A dilution series of HCG (8-4-2-1-0.5-0.25-0 I.U./ml) was prepared with a dilution liquid consisting of one part of * trademark Z
man's serum and 2 parts of 0.05 M phosphate buffer of pM 6.2.
Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immuno-adsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH
6.2, and rotated again at room temperature for 2 hours.
After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of lO ~l of 30% H202 and 20 mg of 5-amino salicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6Ø After 30 minutes the extinction was measured at 460 nm.
In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of l I.U./ml caused the maximum increase. In this tes-t the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enæyme activity, i.e. owing to turbidity of the serum and the peroxidase-like activity of it.
The ~ICG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.
EXAMPLE II
Determination o~ HCG in low concentrations by means of an enzyme/
antigen coupling product.
a) Preparation of antisubstances against rabbit-y-globulin~
Rabbit-y-globulin was isolated from normal rabbit serum by precipitating it with 18% (w/v) solid Na2S04. Anti-bodies against it were generated in a sheep. The injection scheme was:
1(~4(~ 32 _ . ;. _ . _ Day Quant1ty Freund's adjuvant Manner of injection . . . ......... _ 00.5 mg ~ Intramuscularly 140.5 mg +
281 mg + ll 421 mg _ Intravenously 561 mg _ _ On day 70 the sheep was exsanguinated.
b) Preparation of [sheep-anti-(rabbit-y-globulin)]-cellulose.
The y-globulin fraction of the sheep serum described under a) was prepared by precipitating it with 16% (w/v) solid sodium sulphate. This Y-globulin fraction was bound to m-aminobenzyloxymethyl-cellulose, as described in Example I c).
c) Determination of human chorionic gonadotrophin (HCG).
A dilution series of HCG was prepared in 0.01 M phos-phate buffer of pH 6.0, which also contained 2% (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./l, the dilution factor being 2.
To 5 ml of HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see Example I b)), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature Eor 30 minutes, after which 1.5 mg of (sheep-anti~rabbit-y-globulin)]-cellulose were added and the mixture was rotated for 2 hours.
The cellulose was centrifuged for 10 minutes at 3000 r.p.m. and resuspended in 1 ml of a solution of HCG-HRP coupling product, prepared in accordance with Example I a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2% normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of enzyme substrate consisting of 10 ~1 of 30% H202 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of ~L~)9LU~1~2 pH 6Ø The mixture was left to stand for 30 minutes at 25~, after which the extinction was measured at 460 nm. In the supernatant liquid 100% enzyme activity is measured provided that no anti-HCG serum is added to the system.
A dilution series of HCG, prepared with children's - urine as dilution liquid, gave an identical pattern so that also measurings in urine samples can be performed.
The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.
Example III
Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.
a) Preparatlon of the immuno-adsorbent HCG cellulose.
This immuno-adsorbent was prepared by the method mentioned in Example I c), but instead of rabbit-y-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.
b) Purification of antibodies against HCG.
Ten ml of rabbit-anti-HCG serum, prepared in accordance with Example I b), was dilutecl with 90 ml of 0.05 M citrate of pH
5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex*G-25. The immuno-adsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2Ø The fractions were collected in one-half volume of 0.25 M NaHC03, tested for their content of antibodies and protein, and the suitable fractions were frozen.
c) Preparation of the coupling product (anti-HCG)-HRP.
Twenty mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 ~1 of 25%
glutaric aldehyde solution, after which the mixture was shaken * trademark ~ z for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex*G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.
d) Determination of HCG and LH.
Ten ml of a HCG dilution series of HCG and 10 ml of a HCG dilution series of LH were mixed with 5 mg of anti-HCG
cellulose, prepared in accordance with Example I c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures rotated at room temperature for 2 hours. The immuno-adsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6Ø
To the immuno-adsorbent 1 ml of the (anti-HCG)-HRP
coupling product was added in the desired dilution, after which the mixture was rotated again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.
By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per litre respectively could be deterrnined. I~ the centrifugation step is omitted the optimum sample size is 0.5 ml and the sensitivity about 100 I.U. of HCG
per litre, or about 200 I.U. of LH per litre, so that the method ac~ording to the invention yields a 10-20 fold increase in sensitivity.
Example IV
Determination of HCG and anti-HCG.
a) Rabbit-serum was fractionated over DEAE cellulose in accord-ance with the prescription of H.A. Sober and others in J. Am.
Chem. Soc. 78, 756 (1956).
The isolated y-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating * trademark l~(lVl3Z
antibodies in a sheep in accordance with the scheme of Example II a), while besides 100 mg of rabbit-Y-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in Example I c).
From the sheep [anti-(rabbit-y-globulin)] serum prepared the specific antibodies were isolated by -the method described in Example III b) with the immuno-adsorbent prepared.
b) The coupling product [anti-(rabbit-y-globulin)]-HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in Example III c).
c) Determination of anti-HCG.
A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6Ø
Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see Example III a)). The re-action mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b). The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in Example I d).
d) Determination of HCG.
With the reagents prepared, HCG was determined by in-cubating solutions of it with 0.5 ml of rabbit-(anti-HCG) serum in a dilution which in the system described under c) just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under c) with the mixture obtained.
Where use was made of 5 ml of HCG solution, it proved to be possible to demonstrate concentrations of about 10 I.U./l of HCG.
Example V
Determination of insulin in serum.
a) Preparation of insulin-~glucose-oxidase).
Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5.
To this solution 5 ~1 of 25% glutaraldehyde solution were added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex*G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose high-est percentage of enzyme activity could be bound by antibodiesagainst insulin were used in the test system.
b) Preparation of antibodies against insulin.
Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freund's adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.
c) Preparation of anti-substances against cavia y-globulin.
Cavia y-globulin was prepared by adding one volume of a saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33%
saturated (NH4)2S04 solution and then taken up in a physiologic-al salt solution. A sheep was immunized with increasing dosages - of the y-globulin prepared, viz. 0, 5, 1 and 2 mg. The inject-ions were given every 2 weeks, the immunogen being mixed with complete Freund's adjuvant. Two weeks after the last injection another 2 mg of y-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.
d) Preparation of insoluble antibodies against cavia y-globulin.
* trademark Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5% (w/v) CNBr solution, after which the pH was adjusted to 10.5 with an 1 N NaOH-solution, and it was maintained at it for two minutes.
The cellulose was washed with ice water and with 0.1 M NaHC03.
To 10 ml of sheep-anti-(cavia y-globulin) serum 1.6 gm of NaS04 were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16%
(w/v) Na2504 solution, and finally taken up in 10 ml of 0.1 M
NaHC03.
The activated cellulose was mixed with 40 ml of a 0.1 M NaHC03 solution and the 10 ml of y-globulin solution. This suspension was rotated for 40 hours at 4C and washed, twice with 5 ml of 0.5 M NaHC03, twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH
6.2.
e) Determination of insulin in serum.
Four ml of an insulin dilution series in the range of from 0-100 ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml of anti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immuno-adsorbent prepared under d), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2% sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immuno-adsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained 50 mg of glucose, 10 ~gm of peroxidase and 1 mg of 5-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6Ø
The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a 10-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.
Example VI
Determination of oestradiol.
a) Preparation of oestradiol-17-succinyl-HRP.
Fifty mg of oestradiol-17-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of dioxane. To the cold solution (2C) 15 ~1 of isobutylchlorocarbonate were added.
After 30 minutes this solution was mixed with 100 mg of horse-radish peroxidase (HRP) in 7.5 ml of a mixture of dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2C, after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by preci-pitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.
b) Preparation of oestradiol-17-succinyl-BSA.
The preparation was prepared by the mixed anhydride method as described under a). The starting material was 100 mg of oestradiol-17-haemisuccinate and 150 mg of bovine serum albumin (BSA).
~) Preparation of anti-substances against oestradiol.
A sheep was injected every 4 weeks with 4 mg of oestradiol-17-succinyl-BSA in complete Freund's adjuvant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA.
d) Preparation of anti-substances against sheep y-globulin.
Sheep y-globulin was prepared as described in Example II b), this time, however, with 16% w/v sodium sulphate. Rabbits were immunized with this sheep-y-globulin in accordance with the following scheme:
Day Quantity Freund's adjuvant~ Manner of injection ~ 0 200 ~gm + Intramuscularly 14 400 ~gm +
28 800 ~gm + ll 42 800 ~gm l Intravenously Two weeks after the last injection the animals were exsanguinated.
e) Preparation of the immuno-adsorbent [rabbit-anti-(sheep~ -globulin)] cellulose.
The ~-globulin fraction of the anti-sera described under b) was prepared by precipitation with 18% w/v Na2S04.
The product obtained was coupled with cellulose by Gurvich's method described in Example I c).
f) Determination of oestradiol.
A dilution series of oestradiol (0-0.5-1-2-4-8-16 ng/ml) was prepared in phosphate buffer of pH 6Ø Five ml of sample were mixed with 0.5 ml of the sheep-anti-oestradiol-serum in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immuno-adsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M
phosphate buffer of pH 6.0 containing 2% BSA. Then 1 ml of oestradiol-17-succinyl-HRP, diluted to the desired strength Z
wlth the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrlfuged again and the enzyme activity in the supernatant liquid was measured as described in Example I.
By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10, compared with the test without centrifugation step.
Example VII
Determination of cortisol.
a) Preparation of cortisol-21-galactose-oxidase.
Fifty mg of cortisol-21-haemisuccinate and 100 mg of galactoseoxidase were coupled by the mixed anhydride method as described in Example VI a).
b) Preparation of insoluble transcortine.
One hundred mg of transcortine purified by DEAE
cellulose chromatography, followed by hydroxylapatite chromato-graphy, were coupled with 3 gm of Sepharose* 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml o~ 2.5% (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose* was washed with ice-water and with 0.1 M NaHC03, after which 100 mg of transcortine in 20 ml of 0.1 M NaHCO3 were added, and the suspension was shaken at 4C for 24 hours.
After being washed successively with 0.5 M NaHCO3, 0.05 M
citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH
6.0, the Sepharose* was kept in -the last buffer, to which 0.1%
merthiolate had been added.
c) Determination of cortisol.
A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6Ø
* trademark ~ 23 -. _ ~u~z Five ml of each cortisol solution (in 0.05 M phosphate bufferof pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose*, at 4C. After centrifugation 1 ml of cortisol-21-galactose oxidase solution, diluted to a suitable _oncentra-tion in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4C. After re-centrifugation the enzyme activity in the supernatant liquid was determined by - adding 0.5 ml of it to 1.5 ml of substrate consisting of 100 mg of D-galactose, 20 mg of 5-aminosalicylic acid and 10 ~gm of peroxidase in 150 ml of 0.02 M phosphate buffer of pH 6Ø
Finally, after 30 minutes, the extinction was measured at 460 nm.
By this method about 1 ng/ml cortisol could be demon-strated, which means an increase in sensitivity by a factor 10.
* trademark : - 24 -
Claims (14)
1. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bind-able substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;
b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase, c) separating the solid phase from the liquid phase;
d) adding to said solid phase a given quantity of a coupling pro-duct of (1) the component to be determined with (2) an enzyme, which quantity of coupling product is at least sufficient to react with all of the binding partner of the component to be determined; and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;
b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase, c) separating the solid phase from the liquid phase;
d) adding to said solid phase a given quantity of a coupling pro-duct of (1) the component to be determined with (2) an enzyme, which quantity of coupling product is at least sufficient to react with all of the binding partner of the component to be determined; and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten and a low molecular substance, and a protein capable of binding said bind-able substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a) providing a given quantity of the binding partner of the component to be determined in a soluble form;
b) reacting the component to be determined with its binding partner;
c) adding a given quantity of an antibody against said bind-ing partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase;
d) separating the solid phase from the liquid phase;
e) adding to said solid phase a given quantity of a coupling pro-duct of (1) the component to be determined with (2) an enzyme, which quantity of coupling product is at least immuno-chemically equivalent to the quantity, provided in step c), of the insolubilised antibody against said binding partner;
and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
a) providing a given quantity of the binding partner of the component to be determined in a soluble form;
b) reacting the component to be determined with its binding partner;
c) adding a given quantity of an antibody against said bind-ing partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase;
d) separating the solid phase from the liquid phase;
e) adding to said solid phase a given quantity of a coupling pro-duct of (1) the component to be determined with (2) an enzyme, which quantity of coupling product is at least immuno-chemically equivalent to the quantity, provided in step c), of the insolubilised antibody against said binding partner;
and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
3. The process of claim 1 in which the enzyme is an oxido-reductase.
4. The process of claim 2 in which the enzyme is an oxido-reductase.
5. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;
b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase, c) separating the solid phase from the liquid phase, d) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step a), of the insolubilised binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
a) providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;
b) reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase, c) separating the solid phase from the liquid phase, d) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step a), of the insolubilised binding partner of the component to be determined, and e) determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
6. The process of claim 5 wherein the coupling product is obtained by binding to an enzyme the binding partner of the component to be determined.
7. A test pack for the performance of the process of claim 6, comprising:
a) a given quantity of an insoluble form of the binding partner of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolub-ilised binding partner of the component to be determined, and c) a substrate for the determination of enzyme activity of said coupling product.
a) a given quantity of an insoluble form of the binding partner of the component to be determined, b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the insolub-ilised binding partner of the component to be determined, and c) a substrate for the determination of enzyme activity of said coupling product.
8. The process of claim 5 wherein the quantity, provided in step a), of the binding partner of the component to be deter-mined is at least sufficient to react with all of the component to be determined.
9. A test pack for the performance of the process of claim 8, comprising:
a) an insoluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the com-ponent to be determined;
b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised binding partner of the component to be determined; and e) a substrate for the determination of enzyme activity of said coupling product.
a) an insoluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the com-ponent to be determined;
b) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised binding partner of the component to be determined; and e) a substrate for the determination of enzyme activity of said coupling product.
10. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a) providing a given quantity of the binding partner of the component to be determined in a soluble form;
b) reacting the component to be determined with its binding partner;
e) adding a given quantity of antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase;
d) separating the solid phase from the liquid phase;
e) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step c), of the insolubilised antibody against said binding partner; and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be deter-mined.
a) providing a given quantity of the binding partner of the component to be determined in a soluble form;
b) reacting the component to be determined with its binding partner;
e) adding a given quantity of antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase;
d) separating the solid phase from the liquid phase;
e) adding to said solid phase a given quantity of a coupling product obtained by binding to an enzyme a substance capable of reacting specifically with one of the reactants of step b), which quantity of coupling product is at least immunochemically equivalent to the quantity, provided in step c), of the insolubilised antibody against said binding partner; and f) determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be deter-mined.
11. The process of claim 10 wherein the coupling product is obtained by binding to an enzyme the binding partner of the component to be determined.
12. A test pack for the performance of the process of claim 11, comprising:
a) a given quantity of a soluble form of the binding partner of the component to be determined, b) a given quantity of an insoluble form of an antibody against said binding partner, c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised antibody against said binding partner, and d) a substrate for the determination of enzyme activity of said coupling product.
a) a given quantity of a soluble form of the binding partner of the component to be determined, b) a given quantity of an insoluble form of an antibody against said binding partner, c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised antibody against said binding partner, and d) a substrate for the determination of enzyme activity of said coupling product.
13. The process of claim 10 wherein the quantity, provided in step a), of the binding partner of the component to be deter-mined is at least sufficient to react with all of the component to be determined, and wherein the quantity, provided in step c), of the insolubilised antibody against said binding partner is at least sufficient to react with all of said binding partner.
14. A test pack for the performance of the process of claim 13, comprising:
a) a soluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined;
b) an insoluble form of an antibody against said binding partner, in a quantity at least sufficient to react with all of said binding partner;
c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised antibody against said binding partner; and d) a substrate for the determination of enzyme activity of said coupling product.
a) a soluble form of the binding partner of the component to be determined, in a quantity at least sufficient to react with the maximum amount to be measured of the component to be determined;
b) an insoluble form of an antibody against said binding partner, in a quantity at least sufficient to react with all of said binding partner;
c) a given quantity of a coupling product obtained by binding to an enzyme the binding partner of the component to be determined, which quantity of coupling product is at least immunochemically equivalent to the quantity of the in-solubilised antibody against said binding partner; and d) a substrate for the determination of enzyme activity of said coupling product.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL717101728A NL154600B (en) | 1971-02-10 | 1971-02-10 | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1040082B true CA1040082B (en) | 1978-10-10 |
Family
ID=19812444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA134,026A Expired CA958314A (en) | 1971-02-10 | 1972-02-07 | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
CA303,100A Expired CA1040082B (en) | 1971-02-10 | 1978-05-11 | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA134,026A Expired CA958314A (en) | 1971-02-10 | 1972-02-07 | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
Country Status (16)
Country | Link |
---|---|
US (1) | US3791932A (en) |
JP (1) | JPS5247011B1 (en) |
AU (1) | AU468151B2 (en) |
BE (1) | BE779209A (en) |
BR (1) | BR7200729D0 (en) |
CA (2) | CA958314A (en) |
CH (1) | CH573115A5 (en) |
DE (1) | DE2206103B2 (en) |
DK (1) | DK150170C (en) |
ES (1) | ES399608A1 (en) |
FI (1) | FI53894C (en) |
FR (1) | FR2126760A5 (en) |
GB (1) | GB1363565A (en) |
NL (1) | NL154600B (en) |
SE (1) | SE451098B (en) |
ZA (1) | ZA72548B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
Families Citing this family (962)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4203802A (en) * | 1971-05-14 | 1980-05-20 | Syva Company | Inhibitable enzyme amplification assay |
US3875011A (en) * | 1972-11-06 | 1975-04-01 | Syva Co | Enzyme immunoassays with glucose-6-phosphate dehydrogenase |
US3904367A (en) * | 1973-08-15 | 1975-09-09 | Gen Electric | Contrast enhancement for immunological film detection |
US4039652A (en) * | 1973-10-11 | 1977-08-02 | Miles Laboratories, Inc. | Column method of immunoassay employing an immobilized binding partner |
US3951748A (en) * | 1974-11-11 | 1976-04-20 | Medical Products, Inc. | Sensitized matrix for detection of disease |
SE388694B (en) * | 1975-01-27 | 1976-10-11 | Kabi Ab | WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES |
NL7501215A (en) * | 1975-02-01 | 1976-08-03 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING AN ANTIGEN OR ANTIBODY. |
IN142734B (en) * | 1975-04-28 | 1977-08-20 | Miles Lab | |
US4016043A (en) * | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
SE7610683L (en) * | 1975-09-29 | 1977-06-10 | Cordis Corp | METHOD OF DETERMINING THE NERVARON OF AN ANTIGEN ASSOCIATE WITH HEPATITIS |
US4116776A (en) * | 1976-04-19 | 1978-09-26 | International Radioimmune Systems, Inc. | Diagnostic blood test and kit for detecting human chorionic gonadotropin |
GB1572220A (en) * | 1976-10-07 | 1980-07-30 | Mochida Pharm Co Ltd | Immunochemical process of measuring physiologically active substances |
GB1549069A (en) * | 1976-12-10 | 1979-08-01 | Erba Farmitalia | Enzyme linked immunoassay |
JPS5399319A (en) * | 1977-02-09 | 1978-08-30 | Hidematsu Hirai | Novel qualitative and quantitative detecting method and detecting body for antgenic substance |
IT1153999B (en) * | 1977-03-15 | 1987-01-21 | Snam Progetti | COMPOSITION SUITABLE FOR DETERMINING TRIIODOTHYRONIN AND DIAGNOSTIC METHOD USING THE SAME |
IL51668A (en) * | 1977-03-16 | 1981-12-31 | Israel State | Analytical method for the quantitative determination of immunogens and antibodies and a kit therefor |
CA1108516A (en) * | 1977-11-21 | 1981-09-08 | Stanley E. Charm | Antibiotic detection method |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
NL7804144A (en) * | 1978-04-18 | 1979-10-22 | Akzo Nv | DEVICE FOR CLORIMETRIC PROVISIONS. |
NZ190452A (en) * | 1978-05-19 | 1981-04-24 | Becton Dickinson Co | Solid phase assay receptor contacted with analyte and then with labeled analyte |
JPS54170918U (en) * | 1978-05-23 | 1979-12-03 | ||
US4273756A (en) * | 1978-07-28 | 1981-06-16 | Abbott Laboratories | Immunoassay for class specific antibodies |
US4292296A (en) * | 1978-09-12 | 1981-09-29 | Baxter Travenol Laboratories, Inc. | Diagnostic method |
US4240751A (en) * | 1978-11-09 | 1980-12-23 | Akzona Incorporated | Method and apparatus for specific binding substances |
US4374925A (en) * | 1978-11-24 | 1983-02-22 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318707A (en) * | 1978-11-24 | 1982-03-09 | Syva Company | Macromolecular fluorescent quencher particle in specific receptor assays |
JPS55116259A (en) * | 1979-03-01 | 1980-09-06 | Fuji Photo Film Co Ltd | Microimmunoassay method |
JPS55116258A (en) * | 1979-03-01 | 1980-09-06 | Fuji Photo Film Co Ltd | Microimmunoassay method |
US4269938A (en) * | 1979-03-08 | 1981-05-26 | Eastman Kodak Company | Assay of peroxidatively active materials |
US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
GB2059421A (en) * | 1979-10-03 | 1981-04-23 | Self C H | Assay method and reagents therefor |
US4446231A (en) * | 1979-10-03 | 1984-05-01 | Self Colin H | Immunoassay using an amplified cyclic detection system |
US4347312A (en) * | 1980-03-20 | 1982-08-31 | Research Triangle Institute | Detection of antibiotics in milk |
JPS56143955A (en) * | 1980-04-10 | 1981-11-10 | Fujirebio Inc | Method for diagnosis of initial infection of syphilis |
AU543007B2 (en) * | 1980-04-15 | 1985-03-28 | Technicon Instruments Corportion | Agglutination immunoassay |
DE3016575A1 (en) * | 1980-04-30 | 1981-11-05 | Merck Patent Gmbh, 6100 Darmstadt | METHOD FOR THE IMMUNOLOGICAL DETERMINATION OF ENZYMES, MEANS FOR CARRYING OUT THE METHOD AND ITS RELATIONSHIP |
EP0146654A3 (en) * | 1980-06-20 | 1986-08-20 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
US6406920B1 (en) | 1980-06-20 | 2002-06-18 | Inverness Medical Switzerland Gmbh | Processes and apparatus for carrying out specific binding assays |
NL185309C (en) | 1980-07-28 | 1990-03-01 | Akzo Nv | METHOD FOR DETERMINING ANTIGENS USING TWO OR MORE MONOCLONAL ANTIBODIES AND IMMUNE REAGENTS. |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4323647A (en) * | 1980-10-15 | 1982-04-06 | University Of Miami | Steric hindrance enzyme immunoassay |
NZ199286A (en) * | 1980-12-22 | 1986-05-09 | Commw Serum Lab Commission | A method of detecting antibodies or an antigenic or haptenic substance in a sample |
US4517288A (en) * | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US4425438A (en) * | 1981-03-13 | 1984-01-10 | Bauman David S | Assay method and device |
GB2095258B (en) * | 1981-03-19 | 1984-09-05 | Janssen Pharmaceutica Nv | A bright field light microscopic method of localizing tissue antigens |
US4592995A (en) * | 1981-03-30 | 1986-06-03 | Dainippon Pharmaceutical Co., Ltd. | Reagent for streptococcal anti-esterase assay |
US4604365A (en) * | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
JPS57193643U (en) * | 1981-06-03 | 1982-12-08 | ||
US4447528A (en) * | 1981-08-10 | 1984-05-08 | Corning Glass Works | Detecting intrinsic factor blocking site antibody |
WO1983000877A1 (en) * | 1981-08-31 | 1983-03-17 | Icl Scient | Glucose oxidase immunohistochemical detection of antinuclear antibodies |
US4452886A (en) * | 1981-09-21 | 1984-06-05 | Henry Robert P | Novel photon absorbing or emitting polymers and their use as reagents in immunoassay systems |
US4446232A (en) * | 1981-10-13 | 1984-05-01 | Liotta Lance A | Enzyme immunoassay with two-zoned device having bound antigens |
US4753875A (en) * | 1981-11-02 | 1988-06-28 | Ryan James W | Method for assaying proteases with tagged proteinaceous inhibitors |
US4506009A (en) * | 1982-03-30 | 1985-03-19 | University Of California | Heterogeneous immunoassay method |
US4469787A (en) * | 1982-05-14 | 1984-09-04 | Mallinckrodt Inc. | Immunoassay involving soluble complex of second antibody and labeled binding protein |
US4503143A (en) * | 1982-08-20 | 1985-03-05 | Btc Diagnostics Limited Partnership | Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen |
US4530900A (en) * | 1982-09-13 | 1985-07-23 | Seragen Diagnostics Inc. | Soluble insoluble polymers in enzymeimmunoassay |
FR2550799B1 (en) * | 1983-08-17 | 1986-02-21 | Commissariat Energie Atomique | COMPOUND MARKED BY AN ENZYME, ITS PREPARATION METHOD AND ITS USE IN ENZYMOIMMUNOLOGY |
JPS60501570A (en) * | 1983-11-08 | 1985-09-19 | クイデル | Rapid plunger immunoassay method and device |
US4777240A (en) * | 1984-03-08 | 1988-10-11 | Scripps Clinic And Research Foundation | SV40 expression vector containing HBxAg as an expression marker |
US4645828A (en) | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
US4665020A (en) * | 1984-05-30 | 1987-05-12 | United States Department Of Energy | Flow cytometer measurement of binding assays |
US4812395A (en) * | 1984-11-05 | 1989-03-14 | E. I. Du Pont De Nemours And Company | Method for detecting enzymatic activity using particle agglutination |
US4812396A (en) * | 1984-11-05 | 1989-03-14 | E. I. Du Pont De Nemours And Company | Method for detecting enzymatic activity using particle agglutination |
US4713347A (en) * | 1985-01-14 | 1987-12-15 | Sensor Diagnostics, Inc. | Measurement of ligand/anti-ligand interactions using bulk conductance |
US4824784A (en) * | 1985-04-08 | 1989-04-25 | Hygeia Sciences, Incorporated | Chromogenic solution for immunoassay |
US4837395A (en) * | 1985-05-10 | 1989-06-06 | Syntex (U.S.A.) Inc. | Single step heterogeneous assay |
US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
US4868108A (en) * | 1985-12-12 | 1989-09-19 | Hygeia Sciences, Incorporated | Multiple-antibody detection of antigen |
CH670709A5 (en) * | 1986-04-24 | 1989-06-30 | Univ Moskovsk | |
US5039607A (en) * | 1988-05-17 | 1991-08-13 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
US5334513A (en) * | 1988-05-17 | 1994-08-02 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
US5102788A (en) * | 1988-11-21 | 1992-04-07 | Hygeia Sciences, Inc. | Immunoassay including lyophilized reactant mixture |
US5135863A (en) * | 1988-12-23 | 1992-08-04 | Syntex (U.S.A.) Inc. | Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine |
US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
WO1992020820A1 (en) * | 1991-05-15 | 1992-11-26 | Vanderbilt University | Method to determine metastatic potential of tumor cells |
US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US6953573B1 (en) | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
AU679008B2 (en) * | 1993-05-06 | 1997-06-19 | Chiron Diagnostics Corporation | Mixed luminescent conjugate test assays |
WO1995034640A1 (en) * | 1994-06-13 | 1995-12-21 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
US5698686A (en) | 1994-10-20 | 1997-12-16 | Arch Development Corporation | Yeast telomerase compositions |
US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
US5858661A (en) | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
US5807552A (en) * | 1995-08-04 | 1998-09-15 | Board Of Regents, The University Of Texas System | Compositions for conferring immunogenicity to a substance and uses thereof |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
US6942862B2 (en) * | 1996-04-01 | 2005-09-13 | University Of Washington | Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
JP2002514046A (en) | 1996-07-08 | 2002-05-14 | バースタイン テクノロジーズ,インコーポレイティド | Devices and methods for cleavable signaling factors |
US6331275B1 (en) | 1996-07-08 | 2001-12-18 | Burstein Technologies, Inc. | Spatially addressable, cleavable reflective signal elements, assay device and method |
US20050214827A1 (en) * | 1996-07-08 | 2005-09-29 | Burstein Technologies, Inc. | Assay device and method |
US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
US6342349B1 (en) | 1996-07-08 | 2002-01-29 | Burstein Technologies, Inc. | Optical disk-based assay devices and methods |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
WO1999009046A1 (en) * | 1997-08-21 | 1999-02-25 | Quark Biotech, Inc. | Hypoxia-regulated genes |
US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
MXPA00003705A (en) | 1997-10-17 | 2002-04-17 | Univ South Florida | Method to diagnose and monitor cellular immune deficiencies. |
US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
WO2000018885A1 (en) * | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
AU4994899A (en) | 1998-07-13 | 2000-02-01 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
WO2000005582A2 (en) * | 1998-07-21 | 2000-02-03 | Burstein Laboratories, Inc. | Optical disc-based assay devices and methods |
AU8662598A (en) | 1998-07-22 | 2000-02-14 | Syntron Bioresearch, Inc. | Multiple analyte assay device |
US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
AU2150900A (en) | 1998-11-16 | 2000-06-05 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
EP2208782B1 (en) * | 1999-02-04 | 2017-05-31 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
EP1190082A4 (en) * | 1999-06-25 | 2003-07-02 | Yissum Res Dev Co | Method of inducing angiogenesis by micro-organs |
US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
US7167615B1 (en) | 1999-11-05 | 2007-01-23 | Board Of Regents, The University Of Texas System | Resonant waveguide-grating filters and sensors and methods for making and using same |
DE60030466T2 (en) * | 1999-11-19 | 2007-08-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | ASPERGILLUS NIGER BETA-GLUCOSIDASE GENE, PROTEIN, AND USES THEREOF |
US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
US7385106B2 (en) * | 2000-01-24 | 2008-06-10 | Ramot At Tel Aviv University Ltd. | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
DE60142475D1 (en) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | UNIFORM CLASS I (MHC-I) UNIFORM MAJOR HISTORICITY COMPATIBILITY COMPOUNDS, ENCODING CONSTRUCTS, AND METHODS OF THEIR PRODUCTION |
IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
HUP0300810A2 (en) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Artifical vascular grafts, and methods of producing and using same |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
EP2359854B1 (en) | 2000-08-08 | 2013-10-09 | Technion Research and Development Foundation, Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis |
EP1683874A3 (en) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
US7632522B2 (en) * | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
AU2001295850A1 (en) * | 2000-09-28 | 2002-04-08 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
AU2002211201B2 (en) * | 2000-11-02 | 2007-05-31 | The National University Of Singapore | aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display |
IL155940A0 (en) | 2000-11-17 | 2003-12-23 | Vascular Biogenics Ltd | Promoters exhibiting endothelial cell specificity and method of using same |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
EP1341543A4 (en) | 2000-11-24 | 2009-09-02 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US20020172980A1 (en) * | 2000-11-27 | 2002-11-21 | Phan Brigitte Chau | Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems |
US20030003464A1 (en) * | 2000-11-27 | 2003-01-02 | Phan Brigitte C. | Dual bead assays including optical biodiscs and methods relating thereto |
US20040248093A1 (en) * | 2000-11-27 | 2004-12-09 | Coombs James Howard | Magneto-optical bio-discs and systems including related methods |
IL155941A0 (en) * | 2000-11-30 | 2003-12-23 | Yeda Res & Dev | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
KR20030067696A (en) | 2000-11-30 | 2003-08-14 | 모렉큐랄 스킨케어 리미티드 | Diagnosis and treatment of disease |
US20020142287A1 (en) * | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
AU2002230061A1 (en) * | 2001-01-31 | 2002-08-12 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
EP1493014A2 (en) | 2001-04-11 | 2005-01-05 | Burstein Technologies, Inc. | Multi-parameter assays including analysis discs and methods relating thereto |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
MXPA04000397A (en) * | 2001-07-19 | 2004-03-18 | Yissum Res Dev Co | Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof. |
WO2003017817A2 (en) | 2001-08-16 | 2003-03-06 | Bar Ilan University | Diagnosis, prevention and treatment of cancer |
US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
CN100506284C (en) | 2001-10-19 | 2009-07-01 | 脉管生物生长有限公司 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
US6867005B2 (en) | 2001-10-24 | 2005-03-15 | Beckman Coulter, Inc. | Method and apparatus for increasing the dynamic range and accuracy of binding assays |
US6696254B2 (en) | 2001-11-21 | 2004-02-24 | Kimberly-Clark Worldwide, Inc. | Detection and identification of enteric bacteria |
US8178128B2 (en) * | 2001-12-05 | 2012-05-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles containing polymeric nucleic acid homologs |
US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
AU2003216341A1 (en) * | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
SI1487972T1 (en) | 2002-02-21 | 2016-03-31 | Institute Of Virology Slovak Academy Of Sciences | Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use |
WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
US7611723B2 (en) * | 2002-03-26 | 2009-11-03 | Nanocyte Inc. | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue |
WO2003089659A1 (en) * | 2002-04-16 | 2003-10-30 | The Regents Of The University Of California | Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix |
US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
JP2005533102A (en) * | 2002-07-12 | 2005-11-04 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | Method and apparatus for inducing biological processes by micro-organs |
EP2561889A3 (en) | 2002-08-01 | 2013-04-03 | Yeda Research and Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
EP1573047B1 (en) | 2002-08-20 | 2013-11-13 | OpSaniTx LLC | Lectin compositions and methods for modulating an immune response to an antigen |
US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
EP2295980A1 (en) | 2002-10-30 | 2011-03-16 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Molecules and methods using same for measuring non-transferrin bound iron |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
AU2003302701A1 (en) * | 2002-11-29 | 2004-06-23 | Technion Research And Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
AU2003286410A1 (en) | 2002-12-12 | 2004-06-30 | R.B.T (Rakuto Bio Technologies) Ltd. | Methods of producing lignin peroxidase and its use in skin and hair lightening |
ES2571355T3 (en) | 2002-12-16 | 2016-05-24 | Technion Res & Dev Foundation | Culture system without feeder cells or xenocontaminants for human embryonic stem cells |
EP2292762A3 (en) | 2002-12-20 | 2012-12-12 | Board of Regents, The University of Texas System | VMP-like sequences of pathogenic Borrelia species and strains |
ATE546548T1 (en) | 2003-01-02 | 2012-03-15 | Rappaport Family Inst For Res | METHOD FOR PREDICTING THE BENEFIT OF ANTI-OXIDATION THERAPY FOR PREVENTING CARDIOVASCULAR DISEASE IN HYPERGLYCEMIC PATIENTS |
WO2004060791A1 (en) * | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
WO2004106925A2 (en) * | 2003-03-03 | 2004-12-09 | Nagaoka & Co.Ltd. | Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same |
US7786071B2 (en) | 2003-03-04 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same |
CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
ATE517926T1 (en) | 2003-04-04 | 2011-08-15 | Yeda Res & Dev | ANTIBODIES TO INHIBIT THE ACTIVITY OF MMP-2 AND MMP-9 |
CA2520023C (en) | 2003-04-08 | 2013-02-05 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
FR2853551B1 (en) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US20050002953A1 (en) * | 2003-05-06 | 2005-01-06 | Jens Herold | SARS-coronavirus virus-like particles and methods of use |
AU2005234725B2 (en) * | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
RU2350653C2 (en) | 2003-05-22 | 2009-03-27 | Эводжин Лтд. | Methods of abiotic stress tolerance enhancement and/or biomass increase for plants, and plants obtained by method |
US7910523B2 (en) | 2003-05-23 | 2011-03-22 | Board Of Regents, The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors |
US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
EP1636333A4 (en) * | 2003-06-19 | 2007-10-24 | Evogene Ltd | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
EP2719394B1 (en) | 2003-06-30 | 2015-07-29 | Tel Aviv University Future Technology Development L.P. | Peptides for treating amyloid-associated diseases |
CA2542984A1 (en) * | 2003-07-07 | 2005-01-27 | David H. Wagner | Methods for predicting development of auto-immune diseases and treatment of same |
JP2007518394A (en) * | 2003-08-14 | 2007-07-12 | ザ バイオ バランス コーポレイション | Bacterial strain, composition containing the bacterial strain, and use of probiotics thereof |
WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
CA2541535C (en) | 2003-10-07 | 2013-12-10 | Yeda Research And Development Co. Ltd. | Antibodies to nik, their preparation and use |
BRPI0415742A (en) * | 2003-10-23 | 2006-12-19 | Pfizer Producs Inc | vaccine for periodontal disease |
CA2544852A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
WO2005044855A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
ATE476448T1 (en) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES AND ORGAN TRANSPLANT REJECTION |
PT1682177E (en) | 2003-11-04 | 2010-11-29 | Xoma Technology Lt | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
CA2547459C (en) | 2003-11-30 | 2013-10-08 | Yeda Research And Development Co. Ltd | Modulators of nik-siva complex formation for treating immune disorders |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
WO2005061018A1 (en) | 2003-12-22 | 2005-07-07 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring protein backbone |
US8007847B2 (en) * | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
EP1713900A4 (en) * | 2004-01-27 | 2009-06-17 | Compugen Ltd | Methods and systems for annotating biomolecular sequences |
JP2007526337A (en) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | ALK7 and myostatin inhibitors and uses thereof |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
ES2665463T3 (en) * | 2004-06-14 | 2018-04-25 | Evogene Ltd. | Polynucleotides and polypeptides involved in the development of plant fiber and methods of use thereof |
US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
AU2005335203A1 (en) | 2004-09-08 | 2007-02-15 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Compositions and methods for the detection of HIV-1/HIV-2 infection |
WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
US20060095241A1 (en) * | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
CN101065491B (en) | 2004-09-29 | 2012-01-11 | 胶原植物有限公司 | Collagen producing plants and methods of generating and using same |
EP1805319B1 (en) * | 2004-09-29 | 2014-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Recombinant human t2 rnase and uses thereof |
US7781402B2 (en) * | 2004-10-12 | 2010-08-24 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
US20090118132A1 (en) * | 2004-11-04 | 2009-05-07 | Roche Molecular Systems, Inc. | Classification of Acute Myeloid Leukemia |
US7842794B2 (en) | 2004-12-17 | 2010-11-30 | Roche Molecular Systems, Inc. | Reagents and methods for detecting Neisseria gonorrhoeae |
US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
EP1844403A4 (en) * | 2005-01-16 | 2010-06-23 | Zlango Ltd | Iconic communication |
WO2006075335A2 (en) * | 2005-01-16 | 2006-07-20 | Zlango Ltd. | Communications network system and methods for using same |
WO2007080558A2 (en) * | 2006-01-16 | 2007-07-19 | Zlango Ltd. | Communications network system and methods for using same |
EP3028765B1 (en) | 2005-01-31 | 2020-01-08 | Realbio Technologies Ltd. | Method of sequentially transferring liquids through a lateral flow capillary device |
EP2316441A1 (en) | 2005-02-17 | 2011-05-04 | Hadasit Medical Research Services And Development | Bisphosphonates for treating endometriosis |
EP1871402B1 (en) | 2005-02-25 | 2017-07-26 | State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (A.R.O.), Volcani Center | Grape cell culture for treating inflammation |
US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
WO2006109312A2 (en) * | 2005-04-15 | 2006-10-19 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
ES2429564T3 (en) | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component |
US9943481B2 (en) | 2005-05-26 | 2018-04-17 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
JP2008546385A (en) | 2005-06-16 | 2008-12-25 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | Isolated cells and populations containing isolated cells for treating CNS disease |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US20060292559A1 (en) * | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
EP1904526A4 (en) | 2005-07-07 | 2009-10-28 | Fulcrum Sp Ltd | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
CA2614531C (en) | 2005-07-07 | 2015-06-16 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
BRPI0616012A2 (en) | 2005-07-18 | 2011-05-31 | Protalix Ltd | mucosal or intestinal administration of biologically active macromolecules |
JP5017269B2 (en) | 2005-07-26 | 2012-09-05 | ユニヴァーシティ オブ メディシン アンド デンティストリ オブ ニュージャーシィ | Antibody profile specific to tuberculosis |
WO2007019541A2 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc. | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
EP1928479B1 (en) | 2005-08-24 | 2016-06-08 | Yeda Research And Development Co., Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
EP1962719A4 (en) | 2005-08-29 | 2011-05-04 | Technion Res And Dev Of Foundation Ltd | Media for culturing stem cells |
EP1926814B1 (en) * | 2005-09-22 | 2010-04-28 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
BRPI0618965B1 (en) | 2005-10-24 | 2021-01-12 | Evogene Ltd | method to increase a plant's tolerance to an abiotic stress condition, method to increase a plant's biomass, vigor and / or yield, method to increase the efficiency of fertilizer use and / or absorption of a plant |
AU2006321172B2 (en) | 2005-11-29 | 2012-02-23 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP1977312A2 (en) | 2006-01-16 | 2008-10-08 | Zlango Ltd. | Iconic communication |
EP1998800A2 (en) | 2006-01-18 | 2008-12-10 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
CN101416063A (en) | 2006-02-06 | 2009-04-22 | 拉帕波特家族医学科学研究所 | Methods and kit for diagnosing T1DM |
JP5107943B2 (en) | 2006-03-06 | 2012-12-26 | ゼティク テクノロジーズ リミテッド | Methods and compositions for identifying cellular phenotypes |
PT2548951E (en) | 2006-03-23 | 2016-06-14 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2004858A4 (en) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Methods and kits for determining predisposition to warfarin resistance |
MX2008012754A (en) * | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Antibody compositions and methods for treatment of neoplastic disease. |
EA018301B1 (en) | 2006-04-21 | 2013-07-30 | Новартис Аг | Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof |
BRPI0712716A2 (en) * | 2006-05-19 | 2012-05-22 | Teva Pharma | fusion protein, composition, nucleic acid construction, vector, transformed cell, isolated preparation of bacterially expressed inclusion bodies, process for producing a fusion protein, and methods for selectively killing a tumor cell and for treating a tumor cell expressing mesothelin on its surface |
US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
WO2008010228A2 (en) | 2006-07-20 | 2008-01-24 | Yeda Research And Development Co. Ltd. | Photosyntheticorganisms and compositions and methods of generating same |
EP2064319B1 (en) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
WO2008030865A1 (en) * | 2006-09-08 | 2008-03-13 | Wisconsin Alumni Research Foundation | Assay for antibodies to mycobacterium paratuberculosis |
US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
US20100129656A1 (en) | 2006-10-05 | 2010-05-27 | Technion Research & Develpment Foundation Ltd | Microtubes and methods of producing same |
CA2672756C (en) | 2006-12-20 | 2018-11-20 | Evogene Ltd. | Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
ATE548454T1 (en) * | 2007-01-16 | 2012-03-15 | Yissum Res Dev Co | NUCLEIC ACID ACTIVE SUBSTANCES FOR STOPPING H19 FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
US8911996B2 (en) | 2007-01-31 | 2014-12-16 | Technion Research & Development Foundation Limited | Electrospun scaffolds and methods of generating and using same |
CA2676932C (en) | 2007-02-01 | 2015-11-24 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
NZ578657A (en) * | 2007-02-02 | 2012-02-24 | Baylor Res Inst | Multivariable antigens complexed with targeting humanized monoclonal antibody |
WO2008103947A2 (en) * | 2007-02-23 | 2008-08-28 | Baylor Research Institute | Activation of human antigen-presenting cells through clec-6 |
WO2008097866A2 (en) | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
TWI422594B (en) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr) |
US20080233140A1 (en) | 2007-02-23 | 2008-09-25 | Baylor Research Institute | Therapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1 |
TWI440468B (en) * | 2007-02-23 | 2014-06-11 | Baylor Res Inst | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
ES2662036T3 (en) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Sequences that go to the core |
EP2514766A3 (en) | 2007-03-29 | 2013-06-05 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
KR20100015774A (en) | 2007-04-02 | 2010-02-12 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease |
MX355608B (en) | 2007-04-09 | 2018-04-24 | Evogene Ltd | Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants. |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
WO2008129548A2 (en) * | 2007-04-23 | 2008-10-30 | Segev Laboratories Limited | A system for delivering therapeutic agents into living cells and cells nuclei |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
EP2152905B1 (en) | 2007-05-01 | 2015-12-02 | Tel Hashomer Medical Research Infrastructure and Services Ltd. | Methods and kits for detecting fetal cells in the maternal blood |
DK3360571T3 (en) | 2007-05-03 | 2021-01-04 | Agency For Science Tech And Research Astarstar | Antibodies that bind to an intracellular PRL-1 or PRL-3 polypeptide |
ES2660667T3 (en) | 2007-05-07 | 2018-03-23 | Protalix Ltd. | Large-scale disposable bioreactor |
WO2009007980A1 (en) | 2007-07-11 | 2009-01-15 | Yeda Research And Development Co. Ltd. | Nucleic acid construct systems capable of diagnosing or treating a cell state |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
AU2008277257B2 (en) | 2007-07-15 | 2014-03-06 | Hillman, Yitzchak Mr | Disease treatment via antimicrobial peptides or their inhibitors |
BR122020022199B1 (en) | 2007-07-24 | 2021-08-10 | Evogene Ltd | METHOD OF INCREASING THE TOLERANCE OF A PLANT TO ABIOTIC STRESS, BIOMASS AND/OR PRODUCTIVITY OF A PLANT, AND CONSTRUCTION OF ISOLATED NUCLEIC ACID |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
CA2695969A1 (en) | 2007-08-15 | 2009-02-19 | Yeda Research & Development Co. Ltd. | Regulators of mmp-9 and uses therof |
AU2008299318A1 (en) | 2007-09-12 | 2009-03-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating tumors in immune-privileged sites |
US20090068669A1 (en) * | 2007-09-12 | 2009-03-12 | Elias Georges | Slc9a3r1 directed diagnostics for neoplastic disease |
EP2591789B2 (en) | 2007-09-19 | 2022-07-20 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
US8088735B2 (en) | 2007-10-19 | 2012-01-03 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
WO2009059328A2 (en) * | 2007-11-02 | 2009-05-07 | The Johns Hopkins University | Multi- component l2 vaccine for prevention of human papillomavirus infection |
WO2009069123A2 (en) | 2007-11-26 | 2009-06-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions comprising fibrous polypeptides and polysaccharides |
CA2709517C (en) | 2007-12-27 | 2019-02-26 | Evogene Ltd. | Isolated polypeptides, polynucleotides useful for modifying water use efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants |
US20090233295A1 (en) * | 2008-01-29 | 2009-09-17 | Elias Georges | Trim59 directed diagnostics for neoplastic disease |
US20110052501A1 (en) * | 2008-01-31 | 2011-03-03 | Liat Dassa | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9469919B2 (en) | 2008-02-21 | 2016-10-18 | Technion Research & Development Foundation Ltd. | Method of attaching a cell-of-interest to a microtube |
WO2009117462A1 (en) * | 2008-03-18 | 2009-09-24 | Wisconsin Alumini Research Foundation | Mycobacterial culture screening test for mycobacterium avium complex bacteria |
EP2280731A1 (en) * | 2008-04-09 | 2011-02-09 | Technion Research and Development Foundation, Ltd. | Anti human immunodeficiency antibodies and uses thereof |
US20110033473A1 (en) * | 2008-04-09 | 2011-02-10 | Yoram Reiter | Anti influenza antibodies and uses thereof |
EP2508325A3 (en) * | 2008-04-10 | 2013-05-22 | Objet Ltd. | System and method for three dimensional model printing |
PL2288376T3 (en) | 2008-04-18 | 2016-07-29 | Collplant Ltd | Methods of generating and using procollagen |
AU2009239333A1 (en) | 2008-04-21 | 2009-10-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
JP2010043063A (en) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
MX2010012697A (en) * | 2008-05-22 | 2011-03-15 | Evogene Ltd | Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility. |
BRPI0909541A2 (en) | 2008-05-27 | 2016-10-11 | Pluristem Ltd | '' method for treating inflammatory bowel disease '' |
US8663987B2 (en) | 2008-05-28 | 2014-03-04 | Ramot At Tel-Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
US9952211B2 (en) | 2008-06-29 | 2018-04-24 | Realbio Technologies Ltd. | Liquid-transfer device particularly useful as a capturing device in a biological assay process |
EA201170204A1 (en) | 2008-07-16 | 2011-08-30 | ХЬЮМЭБС ЭлЭлСи | ANTIBODIES, NEUTRALIZING HUMAN CYTOMEGALOVIRUS AND THEIR APPLICATION |
EP3009449B1 (en) | 2008-07-16 | 2018-06-06 | Institute for Research in Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
MY155377A (en) * | 2008-07-16 | 2015-10-15 | Baylor Res Inst | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
KR101732056B1 (en) * | 2008-07-25 | 2017-05-02 | 인스티튜트 포 리서치 인 바이오메드슨 | Neutralizing anti-influenza a virus antibodies and uses thereof |
US20120122800A1 (en) | 2008-08-08 | 2012-05-17 | Genisphere, LLC Hatfield, Pennsylvania | Long-Acting DNA Dendrimers and Methods Thereof |
US9580513B2 (en) | 2008-08-08 | 2017-02-28 | Agency For Science, Technology And Research (A*Star) | VHZ for diagnosis and treatment of cancers |
AR073076A1 (en) | 2008-08-18 | 2010-10-13 | Evogene Ltd | USEFUL ISOLATED POLYPYPTIDES AND POLYUCLEOTIDES TO IMPROVE EFFECTIVENESS IN THE USE OF NITROGEN, TOLERANCE TO STRESS ABIOTIC, PERFORMANCE AND BIOMASS IN PLANTS. |
CN105708862B (en) | 2008-09-02 | 2020-11-06 | 普拉里斯坦有限公司 | Adherent cells from placental tissue and their use in therapy |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
WO2010031006A1 (en) | 2008-09-12 | 2010-03-18 | Cryopraxis Criobiologia Ltda. | Ischemic tissue cell therapy |
SG10201504623VA (en) | 2008-09-24 | 2015-07-30 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | Amyloid beta-peptides and methods of use thereof |
EP2341929B1 (en) | 2008-10-06 | 2017-01-25 | University Of Chicago | Compositions and methods related to bacterial emp proteins |
MX345298B (en) | 2008-10-30 | 2017-01-24 | Evogene Ltd | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield. |
WO2010055525A1 (en) | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
US20120014927A1 (en) | 2008-12-03 | 2012-01-19 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
EP2633854B1 (en) | 2008-12-05 | 2015-09-16 | Yeda Research And Development Co. Ltd. | miRNA-9 or miRNA-9* for use in treating ALS |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
EP2808402A3 (en) | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment |
AR074925A1 (en) | 2008-12-29 | 2011-02-23 | Evogene Ltd | POLINUCLEOTIDES, CODED POLYPEPTIDES, AND METHODS TO USE THEM TO MODULATE TOLERANCE TO ABIOTIC STRESS, BIOMASS AND / OR PERFORMANCE IN PLANTS THAT EXPRESS THEM |
DK2376528T3 (en) | 2008-12-29 | 2015-01-05 | Tel Hashomer Medical Res Infrastructure & Services Ltd | PEPTIDES AND COMPOSITIONS FOR PREVENTING cell adhesion, and methods of use thereof |
US8455263B2 (en) | 2008-12-30 | 2013-06-04 | Jin Po Lee | Quantitative analyte assay device and method |
WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
EP2465920B1 (en) | 2009-02-26 | 2017-04-12 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
AU2010220157C1 (en) | 2009-03-02 | 2015-08-06 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
HUE028729T2 (en) | 2009-03-09 | 2017-01-30 | Ramot At Tel-Aviv Univ Ltd | Compositions for prevention and treatment of neurodegenerative diseases |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
EP2414542B1 (en) | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
EP2344179A1 (en) | 2009-04-01 | 2011-07-20 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
SI3281947T1 (en) | 2009-04-03 | 2020-07-31 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
PL2424896T3 (en) | 2009-04-30 | 2016-03-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Anti ceacam1 antibodies and methods of using same |
WO2010134073A1 (en) | 2009-05-19 | 2010-11-25 | Zetiq Technologies Ltd. | Kits for and methods of differential staining of cervical cancer cells and/or tissues |
US8980546B2 (en) | 2009-05-21 | 2015-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the detection of HIV-1-specific antibodies utilizing a Vpu polypeptide |
WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
CN102639146A (en) | 2009-05-27 | 2012-08-15 | 耶达研究及发展有限公司 | Proteasome inhibitors and uses thereof |
EP2435078A1 (en) | 2009-05-28 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Methods of treating inflammation |
CA3095630A1 (en) | 2009-06-10 | 2010-12-16 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
EP2446267A1 (en) | 2009-06-24 | 2012-05-02 | Health Corporation - Rambam | Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
EP2457089B1 (en) | 2009-07-21 | 2019-08-07 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | A method of diagnosing cancer |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
EP2467470A2 (en) | 2009-08-17 | 2012-06-27 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
MX2012002271A (en) * | 2009-08-21 | 2012-07-20 | Gilead Biologics Inc | Therapeutic methods and compositions. |
SG178845A1 (en) | 2009-08-21 | 2012-04-27 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
WO2011021171A1 (en) | 2009-08-21 | 2011-02-24 | Beeologics, Llc | Preventing and curing beneficial insect diseases via plant transcribed molecules |
JP2013502228A (en) * | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス,インク. | In vitro screening assay |
KR20120089274A (en) * | 2009-08-21 | 2012-08-09 | 길리아드 바이오로직스, 인크. | In vivo screening assays |
US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
CN102596179A (en) | 2009-08-27 | 2012-07-18 | 工业研究与发展基金会有限公司 | Liposomal compositions and uses of same |
EP2475381A2 (en) | 2009-09-08 | 2012-07-18 | Yeda Research and Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
EP2475784A1 (en) | 2009-09-08 | 2012-07-18 | Ramot at Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
CN102498127B (en) | 2009-09-17 | 2015-02-25 | 雷蒙特亚特特拉维夫大学有限公司 | Peptides for the treatment of oxidative stress related disorders |
EP2478093A2 (en) | 2009-09-17 | 2012-07-25 | Yeda Research and Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
CN105368836A (en) | 2009-10-14 | 2016-03-02 | 耶路撒冷希伯来大学伊森姆研究发展公司 | Compositions for controlling varroa mites in bees |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
CA2777663A1 (en) | 2009-10-16 | 2011-04-21 | University Of Medicine And Dentistry Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | Knock-out mouse of the mo-1 gene, a gene associated with morbid obesity |
CA2783437C (en) | 2009-11-12 | 2020-08-04 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
EP2498806B1 (en) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
WO2011063198A2 (en) | 2009-11-20 | 2011-05-26 | St. Jude Children's Research Hospital | Methods and compositions for modulating the activity of the interleukin-35 receptor complex |
US20120273993A1 (en) | 2009-11-24 | 2012-11-01 | Collplant Ltd. | Method of generating collagen fibers |
ES2553712T3 (en) | 2009-11-30 | 2015-12-11 | Pluristem Ltd. | Adherent cells of the placenta and their use in the treatment of disease |
WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
CA3172119A1 (en) | 2009-12-28 | 2011-07-07 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
CN107254439B (en) | 2009-12-29 | 2022-01-11 | 加米达细胞有限公司 | Method for enhancing natural killer cell proliferation and activity |
CA2786374C (en) | 2010-01-05 | 2019-01-22 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
SG10201500015TA (en) | 2010-01-12 | 2015-02-27 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
US8697078B2 (en) | 2010-01-27 | 2014-04-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
SG183174A1 (en) | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
US9410131B2 (en) | 2010-02-11 | 2016-08-09 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
WO2011100508A2 (en) | 2010-02-12 | 2011-08-18 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
WO2011104708A2 (en) | 2010-02-24 | 2011-09-01 | Ben Gurion University Of The Negev Research And Development Authority | Methods for inhibiting necrosis |
WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
MY163887A (en) | 2010-03-08 | 2017-11-15 | Monsanto Technology Llc | Polynucleotide molecules for gene regulations in plants |
EP2545176B1 (en) | 2010-03-08 | 2016-05-11 | Yeda Research and Development Co. Ltd. | Recombinant protein production in heterologous systems |
WO2011111050A2 (en) | 2010-03-11 | 2011-09-15 | Jacob Edrei | Methods of generating hydrogen |
EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
JP2013523818A (en) | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | Compositions and methods relating to protein A (SpA) antibodies as enhancers of immune responses |
US8927274B2 (en) | 2010-04-12 | 2015-01-06 | Technion Research & Development Foundation Limited | Populations of pancreatic progenitor cells and methods of isolating and using same |
EP2557913B1 (en) | 2010-04-12 | 2016-08-03 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
RU2012148398A (en) | 2010-04-18 | 2014-05-27 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | MOLECULES AND METHODS OF APPLICATION OF MOLECULES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ErbB / ErbB LIGANDS |
AU2011246876B2 (en) | 2010-04-28 | 2016-06-23 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
EP2566500B1 (en) | 2010-05-05 | 2017-04-12 | Rappaport Family Institute for Research in the Medical Sciences | Ccl1 for use in therapy |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
EP2569417B1 (en) | 2010-05-13 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of adult renal cells and methods of isolating and using same |
EP2575859B1 (en) | 2010-06-03 | 2018-09-19 | Ramot at Tel Aviv University, Ltd. | Methods of treating diabetes and compositions capable of same |
KR20130123357A (en) | 2010-06-07 | 2013-11-12 | 오스나트 에슈어-파비안 | Methods and kits for diagnosing conditions related to hypoxia |
EP2582842A2 (en) | 2010-06-16 | 2013-04-24 | Yissum Research Development Company of The Hebrew University of Jerusalem | Method of diagnosing and treating cancer |
BR112012032126A2 (en) | 2010-06-16 | 2017-10-17 | Futuragene Israel Ltd Empresa Isralense | isolated polynucleotide, nucleic acid structure, nucleic acid structure system, isolated polypeptide, plant, insecticidal composition, and method for controlling or exterminating an insect |
JP6002128B2 (en) | 2010-07-02 | 2016-10-05 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Compositions and methods related to protein A (SpA) variants |
EP2593468B1 (en) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
US9695410B2 (en) | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
EP2593480A2 (en) | 2010-07-15 | 2013-05-22 | Technion Research & Development Foundation Ltd. | Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
CN103108955B (en) | 2010-07-15 | 2015-11-25 | 工业研究与发展基金会有限公司 | For improving the nucleic acid construct of abiotic stress tolerance in plant |
CA2804914A1 (en) | 2010-07-22 | 2012-01-26 | Nadir Askenasy | Regulatory immune cells with enhanced targeted cell death effect |
WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
US20130130311A1 (en) | 2010-07-27 | 2013-05-23 | Yeda Research And Development Co., Ltd. | Methods and systems for assessing clonality of cell cultures |
US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
US8901074B2 (en) | 2010-08-04 | 2014-12-02 | Ramot At Tel-Aviv University | Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases |
SG187830A1 (en) | 2010-08-22 | 2013-03-28 | Univ Ramot | Induced pluripotent stem cells derived from human pancreatic beta cells |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
MX365161B (en) | 2010-08-30 | 2019-05-24 | Evogene Ltd | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance. |
WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
WO2012032520A1 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
US10214722B2 (en) | 2010-09-07 | 2019-02-26 | Technion Research & Development Foundation Limited | Methods for expanding and maintaining human pluripotent stem cells (PSCs) in an undifferentiated state in a single cell suspension culture |
WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
MX357746B (en) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment. |
US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
EP2616539A1 (en) | 2010-09-15 | 2013-07-24 | Ramot at Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
US8951983B2 (en) | 2010-10-17 | 2015-02-10 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
ES2688457T3 (en) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Methods of generating antibodies against metalloenzymes |
US20130227724A1 (en) | 2010-11-03 | 2013-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Transgenic plants with improved saccharification yields and methods of generating same |
US9410132B2 (en) | 2010-11-04 | 2016-08-09 | Ben-Gurion University Of The Negev Research And Development Authority | Acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) and uses thereof |
TW201225972A (en) | 2010-11-15 | 2012-07-01 | Univ Ramot | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
US10117895B2 (en) | 2010-11-17 | 2018-11-06 | Ben-Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
US9574171B2 (en) | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
US20120183960A1 (en) | 2010-12-07 | 2012-07-19 | Enterologics, Inc. | Method for identifying e. coli m-17 |
EP2652125B1 (en) | 2010-12-15 | 2017-04-26 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
CA3095614A1 (en) | 2010-12-22 | 2012-06-28 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing abiotic stress tolerance, yield, growth rate, vigor, biomass, oil content, and/or nitrogen use efficiency of plants |
BR112013016535A2 (en) | 2010-12-28 | 2016-09-20 | Bio Fd&C Co Ltd | plant extracts for the treatment and prevention of infections |
BR112013018516B1 (en) | 2011-01-20 | 2023-11-07 | Protalix Ltd | NUCLEIC ACID EXPRESSION CONSTRUCT, METHOD OF PRODUCING A RECOMBINANT HUMAN ALPHA-GALACTOSIDASE PROTEIN, HUMAN ALFAGALACTOSIDASE PROTEIN, PHARMACEUTICAL COMPOSITION, AND, USE OF A HUMAN ALPHAGALAACTOSIDASE PROTEIN OR A COMPOSITION |
WO2012104851A1 (en) | 2011-01-31 | 2012-08-09 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
CN103597078B (en) | 2011-03-02 | 2016-12-14 | 富途锐基尼以色列有限公司 | There is the antibiotic property transgenic plant of the T3SS albumen of functional disorder |
US9365828B2 (en) | 2011-03-03 | 2016-06-14 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
CA2829110C (en) | 2011-03-06 | 2019-01-15 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
WO2012120518A1 (en) | 2011-03-08 | 2012-09-13 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (pku) |
JP2014510084A (en) | 2011-03-17 | 2014-04-24 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | Bispecific and monospecific asymmetric antibodies and methods for their production |
US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
EP2689008B1 (en) | 2011-03-22 | 2017-09-27 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
CN103648517B (en) | 2011-03-24 | 2016-04-20 | 纽瑞姆制药(1991)有限公司 | Neuroprotective peptide |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
ES2627154T3 (en) | 2011-04-06 | 2017-07-26 | Ramot At Tel-Aviv University Ltd. | Methods of monitoring and analysis of metabolic activity profiles, diagnostic and therapeutic uses thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
ES2768296T3 (en) | 2011-04-15 | 2020-06-22 | Pluristem Ltd | Methods and systems to collect cells |
WO2012150598A2 (en) | 2011-05-03 | 2012-11-08 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
US9192670B2 (en) | 2011-05-04 | 2015-11-24 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
SG195190A1 (en) | 2011-05-31 | 2013-12-30 | Hutchison Biofilm Medical Solutions Ltd | Dispersion and detachment of cell aggregates |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
ES2670596T3 (en) | 2011-06-14 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent the formation of DCIS and progression to breast cancer |
RU2014101662A (en) | 2011-06-23 | 2015-07-27 | Каиима Био Агритех Лтд. | SOFT WHEAT, PLANTS OR PARTS THEREOF WITH PARTIALLY OR FULLY MULTIPLICATED GENOMES, HYBRIDS AND THEIR PRODUCTS, AND ALSO WAYS OF PRODUCING AND APPLICATION |
EP2734545B1 (en) | 2011-07-18 | 2019-03-27 | Institute for Research in Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
CA2841722A1 (en) | 2011-07-20 | 2013-01-24 | Kaiima Bio Agritech Ltd. | Maize plants having a partially or fully multiplied genome and uses thereof |
US20130030452A1 (en) | 2011-07-27 | 2013-01-31 | Health Corporation - Rambam | Devices for surgical applications |
CA2844012C (en) | 2011-08-04 | 2021-03-16 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
WO2013021389A2 (en) | 2011-08-09 | 2013-02-14 | Yeda Research And Development Co.Ltd. | Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
EP2741602A1 (en) | 2011-08-14 | 2014-06-18 | Kaiima Bio Agritech Ltd. | Durum wheat plants having a partially or fully multiplied genome and uses thereof |
EP2753367A4 (en) | 2011-09-07 | 2015-10-14 | Yeda Res & Dev | Olfactory signature and odorant mixture having the same |
SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
ES2657552T3 (en) | 2011-09-08 | 2018-03-05 | Yeda Research And Development Co. Ltd. | New risk biomarkers for lung cancer |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
BR112014005958A2 (en) | 2011-09-13 | 2020-10-13 | Monsanto Technology Llc | agricultural chemical methods and compositions for plant control, method of reducing expression of an accase gene in a plant, microbial expression cassette, method for making a polynucleotide, method of identifying polynucleotides useful in modulating expression of the accase gene and herbicidal composition |
UY34328A (en) | 2011-09-13 | 2013-04-30 | Monsanto Technology Llc | ? COMPOSITIONS AND METHODS TO CONTROL MALEZAS UNDERSTANDING A POLINUCLEOTIDE AND TRANSFER AGENT, AND THAT MODULATE PROTOPORPHYRINOGEN IX OXIDASE. |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
CA2848685A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide |
WO2013040057A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
CN104011068A (en) | 2011-10-21 | 2014-08-27 | 奥古雷克斯生命科学公司 | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
MX356814B (en) | 2011-11-03 | 2018-06-13 | Quark Pharmaceuticals Inc | Methods and compositions for neuroprotection. |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US9736998B2 (en) | 2011-11-23 | 2017-08-22 | Danziger Dan Flower Farm | Otomeria plants |
US9617331B2 (en) | 2011-11-27 | 2017-04-11 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide |
EP2788009B1 (en) | 2011-12-08 | 2016-05-25 | Yeda Research and Development Co. Ltd. | Mammalian fetal pulmonary cells and therapeutic use of same |
WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
CN105833925B (en) | 2011-12-22 | 2018-11-13 | 瑞尔比奥技术有限公司 | sequential lateral flow capillary device for analyte determination |
BR112014015959A8 (en) | 2011-12-22 | 2017-07-04 | Yeda Res & Dev | method for treating an individual in need of a non-syngeneic cell graft or tissue, method for treating an individual in need of an immature hematopoietic cell transplantation, method for inducing donor specific tolerance in an individual in need of a cell non-syngeneic or tissue graft, and method for treating an individual who needs a non-syngeneic cell or tissue graft |
WO2013098820A1 (en) | 2011-12-28 | 2013-07-04 | Kaiima Bio Agritech Ltd. | Cultivated sorghum plant having a partially or fully multiplied genome and uses of same |
US20150216998A1 (en) | 2012-01-01 | 2015-08-06 | Ramot At Tel-Aviv University Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
WO2013118120A2 (en) | 2012-02-06 | 2013-08-15 | Rosetta Green Ltd. | Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
HUE053068T2 (en) | 2012-02-14 | 2021-06-28 | Opko Biologics Ltd | Long-acting coagulation factors and uses thereof |
BR112014021067A2 (en) | 2012-02-19 | 2018-10-30 | Protalix Ltd | oral dosage unit forms and uses thereof for the treatment of gaucher disease |
WO2013124816A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
EP3401393B1 (en) | 2012-02-22 | 2020-02-19 | Exostem Biotec Ltd | Micrornas for the generation of astrocytes |
EP2833714A1 (en) | 2012-03-01 | 2015-02-11 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
EP3483184A1 (en) | 2012-03-07 | 2019-05-15 | Yeda Research and Development Co. Ltd | Compositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same |
EP2828293B1 (en) | 2012-03-20 | 2017-10-25 | Humabs Biomed S.A. | Antibodies that neutralize rsv, mpv and pvm and uses thereof |
WO2013140389A1 (en) | 2012-03-22 | 2013-09-26 | Ramot At Tel-Aviv University Ltd. | Plif multimeric peptides and uses thereof |
US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
IN2014MN01886A (en) | 2012-04-18 | 2015-07-10 | Univ Ramot | |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
BR112014026861A2 (en) | 2012-04-26 | 2018-05-15 | Univ Chicago | coagulase staphylococcal antigens and methods of use |
JP6181158B2 (en) | 2012-05-09 | 2017-08-16 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | TACE prodomain variants as TNF-α inhibitors and their medical use |
US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
SG11201408330XA (en) | 2012-05-24 | 2015-01-29 | Mountgate Group Ltd | Compositions and methods related to prevention and treatment of rabies infection |
MX360866B (en) | 2012-05-24 | 2018-11-09 | A B Seeds Ltd | Compositions and methods for silencing gene expression. |
US9731048B2 (en) | 2012-06-03 | 2017-08-15 | Ben-Gurion University Of The Negev Research And Development Authority | Functionalized titanium binding peptides and implants coated with same |
KR102092025B1 (en) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | Pegylated oxm variants |
EP2870110A1 (en) | 2012-07-03 | 2015-05-13 | Nanospun Technologies Ltd. | Methods and devices for adsorption and biodegradation of petroleum |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
EP3594331A1 (en) | 2012-07-29 | 2020-01-15 | Yeda Research and Development Co. Ltd. | Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms |
WO2014020608A1 (en) | 2012-07-31 | 2014-02-06 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
BR112015001435B1 (en) | 2012-08-06 | 2022-01-18 | Brainstorm Cell Therapeutics Ltd | METHODS FOR GENERATION OF CELLS THAT SECRET BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), GLIA-DERIVED NEUROTROPHIC FACTOR (GDNF), HEPATOCYTE GROWTH FACTOR (HGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN WHICH THESE CELLS DO NOT SECRET FACTOR NERVE GROWTH (NGF) |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
US20140068814A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
EP2895197B1 (en) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
US9701719B2 (en) | 2012-09-27 | 2017-07-11 | Research Development Foundation | Attenuated Chikungunya virus |
WO2014057490A1 (en) | 2012-10-09 | 2014-04-17 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
EP2912062A1 (en) | 2012-10-24 | 2015-09-02 | Yeda Research and Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
US9926564B2 (en) | 2012-10-29 | 2018-03-27 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
MX363326B (en) | 2012-11-20 | 2019-03-20 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides. |
JP2016502536A (en) | 2012-11-29 | 2016-01-28 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Methods to prevent tumor metastasis, treat and prognose cancer, and identify drugs that are putative metastasis inhibitors |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
WO2014106838A2 (en) | 2013-01-01 | 2014-07-10 | A.B. Seeds Ltd. | Methods of introducing dsrna to plant seeds for modulating gene expression |
WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
JP6411372B2 (en) | 2013-01-17 | 2018-10-24 | ノベルラスディクス リミテッド | Method and system for identifying patient-specific driver mutations |
EP2950808B1 (en) | 2013-02-04 | 2019-08-21 | Ramot at Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
CA2902727C (en) | 2013-03-06 | 2020-08-18 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
EP2964668B1 (en) | 2013-03-06 | 2019-11-27 | Protalix Ltd. | Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same |
WO2014138696A1 (en) | 2013-03-07 | 2014-09-12 | University Of Maryland, Baltimore | Immunotherapeutic potential of modified lipooligosaccharides/lipid a |
US10612019B2 (en) | 2013-03-13 | 2020-04-07 | Monsanto Technology Llc | Methods and compositions for weed control |
AU2014249015B2 (en) | 2013-03-13 | 2020-04-16 | Monsanto Technology Llc | Methods and compositions for weed control |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2014147622A1 (en) | 2013-03-21 | 2014-09-25 | Collplant Ltd. | Compositions comprising collagen and prp for tissue regeneration |
ES2643321T3 (en) | 2013-03-24 | 2017-11-22 | Biokine Therapeutics Ltd. | A combination of a CXCR4 antagonist and cytarabine for use in the treatment of myeloid leukemia |
RU2015149680A (en) | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | AGENTS TO SUPPRESS ACTIVITY AND / OR REDUCE THE NUMBER OF BCL-XL AND / OR BCL-W |
CN105531365A (en) | 2013-04-23 | 2016-04-27 | 耶达研究及发展有限公司 | Isolated naive pluripotent stem cells and methods of generating same |
EP2989119B1 (en) | 2013-04-25 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Use of inhibitory peptides for the treatment of inflammatory diseases |
WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
SG11201509636XA (en) | 2013-05-27 | 2015-12-30 | Rakuto Bio Technologies Ltd | Enzymatic system-containing cosmetic compositions |
ES2938044T3 (en) | 2013-06-24 | 2023-04-04 | Univ Ramot | Omentum-based structure and delivery system |
BR112016000555B1 (en) | 2013-07-19 | 2022-12-27 | Monsanto Technology Llc | METHOD FOR CONTROLLING AN INFESTATION OF THE LEPTINOTARSA SPECIES IN A PLANT, INSECTICIDAL COMPOSITION AND CONSTRUCTION OF RECOMBINANT DNA |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
EP3039030B1 (en) | 2013-08-29 | 2018-09-19 | Yeda Research and Development Co. Ltd. | Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure |
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants composed of cellular scaffolds and a vascular pedicle |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
ES2717446T3 (en) | 2013-09-17 | 2019-06-21 | Yeda Res & Dev | Peptides derived from ERK and uses thereof |
CN105960453A (en) | 2013-10-01 | 2016-09-21 | 卡迪马干细胞有限公司 | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (ALS) |
LT3052192T (en) | 2013-10-02 | 2020-12-10 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
KR102444140B1 (en) | 2013-10-21 | 2022-09-15 | 옵코 바이오로직스 리미티드 | Long-acting polypeptides and methods of producing and administering same |
EP3060656A1 (en) | 2013-10-24 | 2016-08-31 | Yeda Research and Development Co., Ltd. | Polynucleotides encoding brex system polypeptides and methods of using same |
AU2014343214B2 (en) | 2013-10-31 | 2020-04-09 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia with a FLT3 mutation |
CA2929533C (en) | 2013-11-04 | 2023-06-06 | Monsanto Technology Llc | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
EP3074044A2 (en) | 2013-11-28 | 2016-10-05 | Yeda Research and Development Co., Ltd. | Synaptojanin-2 inhibitors and uses thereof |
ES2697757T3 (en) | 2013-12-10 | 2019-01-28 | Yeda Res & Dev | Use of enzymes that catalyze the synthesis of pyruvate from formate and acetyl-CoA and bacteria that express the same |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
MX368629B (en) | 2014-01-15 | 2019-10-08 | Monsanto Technology Llc | Methods and compositions for weed control using epsps polynucleotides. |
US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
US20170042893A1 (en) | 2014-02-03 | 2017-02-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of casein kinase i inhibitors for depleting stem cells |
WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
EP3102607B1 (en) | 2014-02-06 | 2018-08-22 | Yeda Research and Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
US20170101633A1 (en) | 2014-02-10 | 2017-04-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
WO2015121859A1 (en) | 2014-02-11 | 2015-08-20 | Brainstorm Cell Therapeutics Ltd. | Method of qualifying cells |
WO2015132784A1 (en) | 2014-03-03 | 2015-09-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
EP2923709A1 (en) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multi-component-multistage malaria vaccine |
BR112016022711A2 (en) | 2014-04-01 | 2017-10-31 | Monsanto Technology Llc | compositions and methods for insect pest control |
CA2945438C (en) | 2014-04-10 | 2023-08-22 | Bonus Therapeutics Ltd. | Bone repair compositions |
DK4026917T3 (en) | 2014-04-14 | 2024-02-12 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Method and kit for determining cell or tissue death or the tissue or cell origin of DNA by DNA methylation analysis |
EP3132057B1 (en) | 2014-04-17 | 2019-10-16 | Yeda Research and Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
AP2016009504A0 (en) | 2014-04-27 | 2016-10-31 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
EP3058085B1 (en) | 2014-04-28 | 2021-02-17 | Yeda Research and Development Co., Ltd. | Microbiome response to agents |
WO2015170325A2 (en) | 2014-05-04 | 2015-11-12 | Forrest Innovations Ltd. | Compositions and methods for reducing pathogen-induced citrus greening |
CN106659774A (en) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | Methods and compositions for treating autoimmune and inflammatory conditions |
US10294482B2 (en) | 2014-05-22 | 2019-05-21 | Yeda Research And Development Co. Ltd. | Recombinant microorganisms capable of carbon fixation |
WO2015186129A1 (en) | 2014-06-02 | 2015-12-10 | Technion Research & Development Foundation Limited. | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
EP3149155B1 (en) | 2014-06-02 | 2020-09-23 | Kadimastem Ltd. | Methods of inducing myelination and maturation of oligodendrocytes |
CA2953347A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3145951A1 (en) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
JP6587288B2 (en) | 2014-06-25 | 2019-10-09 | テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド | Its use for the identification as well as the diagnosis and treatment of cancer stem cells |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
EP3160448A4 (en) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
ES2799404T3 (en) | 2014-07-15 | 2020-12-17 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Isolated CD44 polypeptides and uses thereof |
CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
CN106715719B (en) | 2014-07-21 | 2022-08-02 | 福尔生物治疗有限公司 | Method for determining drug response to patient specific mutations |
RU2021123470A (en) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | COMPOSITIONS AND METHODS FOR COMBATING PESTS |
CN108064274A (en) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | For cultivating the culture medium of multipotential stem cell |
CN111624346A (en) | 2014-08-14 | 2020-09-04 | 米密德诊断学有限公司 | Kit for predicting and/or determining prognosis |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | Nmda receptor antagonists for treating gaucher disease |
US10174320B2 (en) | 2014-09-21 | 2019-01-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Downregulating miR-132 for the treatment of lipid related disorders |
WO2016055950A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Combination of human cytomegalovirus neutralizing antibodies |
DE102015220401B4 (en) | 2014-10-20 | 2022-12-29 | Gen-Probe Incorporated | Erythrocyte Lysis Solution |
WO2016075697A1 (en) | 2014-11-13 | 2016-05-19 | Enzootic Holdings Ltd. | Functional sex-reversal of decapod crustacean females |
WO2016075546A2 (en) | 2014-11-14 | 2016-05-19 | Antonio Lanzavecchia | Antibodies that neutralize ebola virus and uses thereof |
EP3220945A2 (en) | 2014-11-17 | 2017-09-27 | Yeda Research and Development Co., Ltd. | Methods of treating diseases related to mitochondrial function |
EP3221470B1 (en) | 2014-11-17 | 2019-08-14 | Yeda Research and Development Co., Ltd. | Method of analyzing microbiome |
BR122020023406B1 (en) | 2014-11-18 | 2023-10-31 | Institut Pasteur | ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSAVIRUS, NUCLEIC ACID MOLECULES, VECTOR, ISOLATED CELL, PHARMACEUTICAL COMPOSITION, USES THEREOF, AND KIT OF PARTS |
EP3221455B1 (en) | 2014-11-20 | 2020-08-12 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
CN107208070B (en) | 2014-11-26 | 2021-09-07 | 技术创新动力基金(以色列)有限合伙公司 | Targeted elimination of bacterial genes |
CA2968808A1 (en) | 2014-11-27 | 2016-06-02 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
WO2016092555A2 (en) | 2014-12-11 | 2016-06-16 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
ES2880346T3 (en) | 2014-12-30 | 2021-11-24 | Cell Cure Neurosciences Ltd | Evaluation of retinal pigment epithelial cell populations |
JP6882981B2 (en) | 2014-12-30 | 2021-06-02 | セル キュア ニューロサイエンシズ リミテッド | RPE cell population and how to make it |
KR102359257B1 (en) | 2014-12-30 | 2022-02-07 | 셀 큐어 뉴로사이언시스 리미티드 | How to treat retinal disease |
MX2017008567A (en) | 2015-01-04 | 2018-04-26 | Protalix Ltd | Modified dnase and uses thereof. |
WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
PL3256589T3 (en) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
EP3268475B1 (en) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Anti amphiregulin antibodies, compositions comprising same and uses thereof |
CA2981142A1 (en) | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
EP3277308A1 (en) | 2015-03-31 | 2018-02-07 | Yeda Research and Development Co., Ltd. | Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof |
WO2016157192A1 (en) | 2015-04-01 | 2016-10-06 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
HUE057044T2 (en) | 2015-04-07 | 2022-04-28 | Ela Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |
EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
CA2986202C (en) | 2015-04-27 | 2023-08-22 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
ES2911341T3 (en) | 2015-04-29 | 2022-05-18 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Antiphytopathogenic compositions |
US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
WO2016178207A1 (en) | 2015-05-04 | 2016-11-10 | Ramot At Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
MX2017014787A (en) | 2015-05-21 | 2018-05-01 | Yeda Res & Dev | Bacterial populations for promoting health. |
KR20180014754A (en) | 2015-05-29 | 2018-02-09 | 옵코 바이오로직스 리미티드 | Pegylated oxine tomoldulin variant |
HRP20211510T1 (en) | 2015-06-01 | 2021-12-24 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
CN107750125A (en) | 2015-06-02 | 2018-03-02 | 孟山都技术有限公司 | For by the composition and method in delivery of polynucleotides to plant |
WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
EP3302559B1 (en) | 2015-06-04 | 2022-01-12 | University of Southern California | Lym-1 and lym-2 targeted car cell immunotherapy |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
ES2917884T3 (en) | 2015-06-18 | 2022-07-12 | Yeda Res & Dev | Conditioning protocols and their use for tissue regeneration |
KR102172937B1 (en) | 2015-06-19 | 2020-11-03 | 옵코 바이오로직스 리미티드 | Long-acting coagulation factor and its preparation method |
US20180179274A1 (en) | 2015-06-26 | 2018-06-28 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
ES2963038T3 (en) | 2015-07-16 | 2024-03-25 | Yeda Res & Dev | Use of anti-third central memory T cells |
CN111375066B (en) | 2015-07-16 | 2023-04-25 | 百欧肯治疗有限公司 | Compositions and methods for treating cancer |
US10668094B2 (en) | 2015-07-19 | 2020-06-02 | Yeda Research And Development Co. Ltd. | Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure |
CA2993023C (en) | 2015-07-22 | 2020-04-28 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
WO2017021963A1 (en) | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
CN108138144A (en) | 2015-08-05 | 2018-06-08 | 细胞治疗神经科学有限公司 | The preparation of retinal pigment epithelium |
EA201890442A1 (en) | 2015-08-05 | 2018-07-31 | Селл Кьюр Нейросайансес Лтд. | OBTAINING PHOTORECEPTORS FOR THE TREATMENT OF RETITAL DISEASES |
EP3334449B1 (en) | 2015-08-10 | 2021-09-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using cd24 |
WO2017025967A1 (en) | 2015-08-13 | 2017-02-16 | Forrest Innovations Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
EP3365376A1 (en) | 2015-10-25 | 2018-08-29 | Yeda Research and Development Co., Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
WO2017072763A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
CA3187317A1 (en) | 2015-10-27 | 2017-05-04 | Jay Pharma, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method of inducing cardiomyocytes proliferation and treating heart diseases |
WO2017077539A1 (en) | 2015-11-03 | 2017-05-11 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
JP6909230B2 (en) | 2015-11-30 | 2021-07-28 | カディマステム リミテッド | Methods for Differentiation and Purification of Pancreatic Endocrine Cells |
EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
EP3389678B1 (en) | 2015-12-16 | 2022-06-15 | Ramot at Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
US10561706B2 (en) | 2015-12-28 | 2020-02-18 | B. G. Negev Technologies And Applications | Isolated polypeptide and compositions comprising same |
CA3009127A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
WO2017122203A1 (en) | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
EP3402513A4 (en) | 2016-01-13 | 2019-10-23 | Medlmmune, LLC | Method of treating influenza a |
MX2018008910A (en) | 2016-01-21 | 2019-03-28 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Parthenocarpic plants and methods of producing same. |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | Composition comprising sp1 and carbon based nanoparticles and uses thereof |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive yarn |
US11261433B2 (en) | 2016-01-31 | 2022-03-01 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
EP3411390A1 (en) | 2016-02-04 | 2018-12-12 | Yeda Research and Development Co. Ltd | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
US20190142875A1 (en) | 2016-02-14 | 2019-05-16 | Yeda Research And Development Co. Ltd. | Microbiome-based diagnosis, prediction and treatment of relapsing obesity |
WO2017138008A2 (en) | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
AU2017220830A1 (en) | 2016-02-16 | 2018-09-06 | Yeda Research And Development Co. Ltd. | Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth |
US11053476B2 (en) | 2016-02-23 | 2021-07-06 | Exostem Biotec Ltd. | Generation of cancer stem cells and use thereof |
BR112018067522A2 (en) | 2016-03-01 | 2019-02-05 | Univ Of Rijeka Faculty Of Medicine | human poliovirus receptor (pvr) specific antibodies |
IL294121B2 (en) | 2016-03-03 | 2023-09-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods of isolating barrel-like proteases and identifying peptides processed thereby |
US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
DE202017007129U1 (en) | 2016-04-27 | 2019-08-29 | Gen-Probe Incorporated | Lysis reagent for blood cells |
WO2017203520A1 (en) | 2016-05-22 | 2017-11-30 | Yeda Research And Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of agents for treating drug resistant tumors |
WO2017208247A1 (en) | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
WO2017212476A1 (en) | 2016-06-05 | 2017-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Novel molecules for the treatment of inflammation |
US20190160152A1 (en) | 2016-06-09 | 2019-05-30 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
CN109689894A (en) | 2016-06-19 | 2019-04-26 | 耶路撒冷希伯来大学伊萨姆研发有限公司 | Chemotherapy resistance is screened in human haploid cell |
US10961504B2 (en) | 2016-06-27 | 2021-03-30 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory T cells |
EP4184167A1 (en) | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Early diagnosis of infections |
WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
US20190224244A1 (en) | 2016-07-11 | 2019-07-25 | Bonus Therapeutics Ltd. | Cell compositions for tissue regeneration |
IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combination therapy to increase endogenous nitric oxide (no) synthesis |
WO2018011805A2 (en) | 2016-07-11 | 2018-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
BR112019000610A2 (en) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | long-acting coagulation factor vii and production methods thereof |
WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
WO2018020489A1 (en) | 2016-07-24 | 2018-02-01 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
US10982252B2 (en) | 2016-08-08 | 2021-04-20 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
EP3504553B1 (en) | 2016-08-10 | 2022-04-20 | Memed Diagnostics Ltd. | System and method for analysis of biological data |
ES2925527T3 (en) | 2016-08-14 | 2022-10-18 | Univ Ramot | Exosomes derived from mesenchymal cells to treat neurological disorders |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
JP2020501506A (en) | 2016-09-07 | 2020-01-23 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | Anti-NKp46 antibody and therapeutic use thereof |
EP3512943B1 (en) | 2016-09-14 | 2023-04-12 | Yeda Research and Development Co. Ltd. | Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens |
US11385241B2 (en) | 2016-09-29 | 2022-07-12 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing |
IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of a circadian rhythm disorder |
US10662226B2 (en) | 2016-10-28 | 2020-05-26 | The Regents of the University of Caiifomia | Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers |
WO2018087759A1 (en) | 2016-11-10 | 2018-05-17 | Yeda Research And Development Co. Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
EP3545095A1 (en) | 2016-11-28 | 2019-10-02 | Yeda Research and Development Co., Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
EP3548015A1 (en) | 2016-11-30 | 2019-10-09 | Yeda Research and Development Co. Ltd. | Methods of treating liver toxicity and disorders |
MX2018016003A (en) | 2016-12-01 | 2019-05-16 | Univ Ramot | Combined treatment for nerve injuries. |
WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods of culturing t cells and uses of same |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
JP2020511539A (en) | 2017-03-16 | 2020-04-16 | リネージ セル セラピューティクス インコーポレイテッド | Method to measure the therapeutic effect of retinal disease treatment |
ES2963461T3 (en) | 2017-04-05 | 2024-03-27 | Yeda Res & Dev | Ex vivo culture system and methods of its use |
BR112019021824A2 (en) | 2017-04-19 | 2020-06-02 | Institute For Research In Biomedicine | VACCINES AGAINST MALARIA AND PLASMODE SPOROZOYTE BINDING ANTIBODIES |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Methods of treating psychiatric stress disorders |
EP3621991A2 (en) | 2017-05-10 | 2020-03-18 | Ariel Scientific Innovations Ltd. | Methods of purifying antibodies |
ES2939298T3 (en) | 2017-05-21 | 2023-04-20 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Combination of markers for cancer diagnosis |
EP3634991A1 (en) | 2017-05-23 | 2020-04-15 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
EP3630973A1 (en) | 2017-05-31 | 2020-04-08 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
US20200340057A1 (en) | 2017-07-13 | 2020-10-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dna targets as tissue-specific methylation markers |
US20200165671A1 (en) | 2017-07-13 | 2020-05-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detecting tissue-specific dna |
WO2019012544A1 (en) | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combination therapy for the treatment of cancer |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses |
US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof |
AU2018336126A1 (en) | 2017-09-19 | 2020-04-30 | Tropic Biosciences UK Limited | Modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells |
JP2021502125A (en) | 2017-11-09 | 2021-01-28 | ピンテオン セラピューティクス インコーポレイテッド | Methods and Compositions for the Preparation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with improved properties |
CN111615332A (en) | 2017-11-29 | 2020-09-01 | 维德奥特有限公司 | Compositions, kits and methods for controlling amaranth weeds |
IL274979B1 (en) | 2017-11-29 | 2024-03-01 | Univ Ramot | Methods of preventing or treating neurogenic shock |
WO2019106680A1 (en) | 2017-12-03 | 2019-06-06 | Yeda Research And Development Co. Ltd. | Treatment of an ischemic heart disease |
EP3723785A1 (en) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
WO2019130313A1 (en) | 2017-12-28 | 2019-07-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Endoplasmic reticulum targeting signal |
WO2019155459A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Inhibitors of the 20s proteasome |
EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
WO2019167047A1 (en) | 2018-02-28 | 2019-09-06 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
WO2019175869A1 (en) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Treatment of a heart disease |
WO2019183500A1 (en) | 2018-03-23 | 2019-09-26 | Hung Chiung Yu | Coccidioides antigens and methods of their use |
JP2021519283A (en) | 2018-03-29 | 2021-08-10 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | Vesicles containing PTEN inhibitors and their use |
EP3774047A1 (en) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Use of electric field gradients to control gene expression |
IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
US20210121491A1 (en) | 2018-05-27 | 2021-04-29 | Biolinerx Ltd. | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors |
EP3802839A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Nucleic acid constructs and methods of using same |
WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
US11873322B2 (en) | 2018-06-25 | 2024-01-16 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
AU2019297677A1 (en) | 2018-07-04 | 2021-02-25 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
WO2020012467A2 (en) | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
JP7395517B2 (en) | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | Peptide compounds and their therapeutic uses |
CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
US20210310082A1 (en) | 2018-07-31 | 2021-10-07 | Collplant Ltd. | Tobacco transgenic event and methods for detection and use thereof |
IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
CN113227359A (en) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | Methods of modulating polarization of M2 macrophages and uses thereof in therapy |
CA3112135A1 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
WO2020065647A1 (en) | 2018-09-25 | 2020-04-02 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
MX2021006756A (en) | 2018-12-19 | 2021-09-28 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof. |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
WO2020170239A1 (en) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
CN113692225B (en) | 2019-03-05 | 2023-04-18 | 以色列农业和农村发展部农业研究组织(范卡尼中心) | Genome-edited birds |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
KR20220004985A (en) | 2019-03-27 | 2022-01-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Recombinant protein with CD40 activation properties |
WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
EP3946611A2 (en) | 2019-03-31 | 2022-02-09 | Yeda Research and Development Co. Ltd | Anti-viral and anti-tumoral compounds |
IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Compositions comprising the propeptide of lysyl oxidase and uses thereof |
EP3969619A1 (en) | 2019-05-13 | 2022-03-23 | Yeda Research and Development Co. Ltd | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutated neopeptides |
EP3973049A1 (en) | 2019-05-22 | 2022-03-30 | Hadasit Medical Research Services and Development Ltd. | Methods of culturing human pluripotent cells |
GB2598520A (en) | 2019-05-28 | 2022-03-02 | Univ Shanghai Tech | Composition and methods to treat ectodermal dysplasia 2, Clouston type |
JP2022536326A (en) | 2019-06-12 | 2022-08-15 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | Method for producing oligodendrocytes |
EP3983540A1 (en) | 2019-06-16 | 2022-04-20 | Yeda Research and Development Co. Ltd | Method for stabilizing intracellular rna |
US20220251193A1 (en) | 2019-06-27 | 2022-08-11 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
JP2022538647A (en) | 2019-07-04 | 2022-09-05 | ウッコ インコーポレイテッド | De-epitoped alpha gliadin and its use for the management of celiac disease and gluten sensitivity |
WO2021005599A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
EP3999851A4 (en) | 2019-07-16 | 2023-04-12 | Ramot at Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
EP4004548A1 (en) | 2019-07-29 | 2022-06-01 | Yeda Research and Development Co. Ltd | Methods of treating and diagnosing lung cancer |
EP4004212A1 (en) | 2019-07-30 | 2022-06-01 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
WO2021033176A1 (en) | 2019-08-22 | 2021-02-25 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
EP4021463A1 (en) | 2019-08-27 | 2022-07-06 | Yeda Research and Development Co. Ltd | Treatment of bacterial vaginosis |
CN114630680A (en) | 2019-08-29 | 2022-06-14 | 维尔生物科技有限公司 | Antibody compositions and methods for treating hepatitis b virus infection |
WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembly of protein complexes on a chip |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
US20240117386A1 (en) | 2019-10-31 | 2024-04-11 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
JP2023501004A (en) | 2019-11-11 | 2023-01-17 | アイビーアイ-エージー イノベイティブ バイオ インセクティサイズ リミテッド | Insect control nanobodies and their uses |
US20230022576A1 (en) | 2019-11-19 | 2023-01-26 | Protalix Ltd. | Removal of constructs from transformed cells |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | Method of treating alzheimer’s disease |
KR20220131895A (en) | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Novel immunotherapy targeting PD-1 using anti-PD-1/IL-15 immunocytokines |
CN112898414A (en) | 2019-12-04 | 2021-06-04 | 珠海泰诺麦博生物技术有限公司 | Anti-human cytomegalovirus antibodies and uses thereof |
EP4077731A1 (en) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnosis of frontotemporal dementia |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | Systems and methods for identifying cells that have undergone genome editing |
IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods of treating atopic dermatitis |
US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
IL272074A (en) | 2020-01-15 | 2021-07-29 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Methods of treating cancer |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
WO2021156878A2 (en) | 2020-02-09 | 2021-08-12 | Nlc Pharma Ltd | Rapid detection test for sars-cov-2 |
IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | Method for analyzing cell clusters |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
WO2021178637A1 (en) | 2020-03-05 | 2021-09-10 | Iowa State University Research Foundation, Inc. | IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2 |
US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
AU2021245409A1 (en) | 2020-03-29 | 2022-11-24 | Yeda Research And Development Co. Ltd. | Variants of beta-glucocerebrosidase for use in treating Gaucher Disease |
IL296698A (en) | 2020-03-31 | 2022-11-01 | Biomuse Ltd | Bacteria for the prevention and treatment of smoke-induced lung damage |
EP4133107A1 (en) | 2020-04-06 | 2023-02-15 | Yeda Research and Development Co. Ltd | Methods of diagnosing cancer and predicting responsiveness to therapy |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
JP2023525140A (en) | 2020-05-13 | 2023-06-14 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Recombinant proteins with OX40 activation properties |
IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Indexing spatial information for a single-cell downstream applications |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
BR112022026316A2 (en) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | Mage-a1 specific t cell receptor and uses thereof |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Method for modulating weight |
EP4217370A2 (en) | 2020-09-23 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods and compositions for treating coronaviral infections |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | Method of diagnosing breast cancer |
EP4225902A1 (en) | 2020-10-05 | 2023-08-16 | Protalix Ltd. | Dicer-like knock-out plant cells |
KR20230104160A (en) | 2020-10-07 | 2023-07-07 | 프로탈릭스 리미티드 | long-acting deoxyribonuclease (DNASE) |
EP4228637A1 (en) | 2020-10-15 | 2023-08-23 | Yeda Research and Development Co. Ltd | Method of treating myeloid malignancies |
IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for rna editing and methods of using same |
WO2022097157A2 (en) | 2020-11-09 | 2022-05-12 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
AU2021387979A1 (en) | 2020-11-26 | 2023-03-30 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling ubiquitination of mlkl for treatment of disease |
WO2022144883A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
AU2021411103A1 (en) | 2020-12-28 | 2023-07-13 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
JP2024502377A (en) | 2021-01-10 | 2024-01-18 | スーパーミート ザ エッセンス オブ ミート リミテッド | Pluripotent stem cell aggregates and microtissues obtained therefrom for cultured meat industry |
WO2022153286A1 (en) | 2021-01-14 | 2022-07-21 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection |
TW202245838A (en) | 2021-01-26 | 2022-12-01 | 美商維爾生物科技股份有限公司 | Compositions and methods for treating hepatitis b virus infection |
JP2024506955A (en) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | How to make a vaccine |
JP2024506954A (en) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Genetically modified bacteria for vaccine production |
WO2022189558A2 (en) | 2021-03-10 | 2022-09-15 | Mabylon Ag | Antibodies against tdp-43 and methods of using the same |
IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for ex-utero mouse embryonic development |
CA3213424A1 (en) | 2021-03-30 | 2022-10-06 | Lior Moshe ZELCBUCH | Pseudomonas bacteriophage and uses thereof |
IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders |
CA3218291A1 (en) | 2021-05-12 | 2022-11-17 | Lior Moshe ZELCBUCH | Staphylococcus bacteriophage and uses thereof |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease |
WO2022259242A1 (en) | 2021-06-06 | 2022-12-15 | Yeda Research And Development Co. Ltd. | Combined treatment for cancer |
CA3230677A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
KR20240035997A (en) | 2021-06-16 | 2024-03-19 | 시드엑스 테크놀로지스 인코포레이티드 | Methods for selecting Matiola seeds |
NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
WO2023275255A1 (en) | 2021-07-02 | 2023-01-05 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
AU2022313138A1 (en) | 2021-07-18 | 2024-02-29 | Gamida-Cell Ltd. | Therapeutic nk cell populations |
WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
CA3226947A1 (en) | 2021-08-03 | 2023-02-09 | Muhammad YASSIN | Engineered tcr complex and methods of using same |
WO2023018621A1 (en) | 2021-08-10 | 2023-02-16 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
WO2023105526A1 (en) | 2021-12-08 | 2023-06-15 | Yeda Research And Development Co. Ltd. | Multipotent lung progenitor cells for lung regeneration |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE341239B (en) * | 1967-09-06 | 1971-12-20 | Pharmacia Ab | |
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
-
1971
- 1971-02-10 NL NL717101728A patent/NL154600B/en not_active IP Right Cessation
-
1972
- 1972-01-27 US US00221447A patent/US3791932A/en not_active Expired - Lifetime
- 1972-01-27 ZA ZA720548A patent/ZA72548B/en unknown
- 1972-02-01 GB GB469672A patent/GB1363565A/en not_active Expired
- 1972-02-02 AU AU38552/72A patent/AU468151B2/en not_active Expired
- 1972-02-04 CH CH165572A patent/CH573115A5/xx not_active IP Right Cessation
- 1972-02-07 CA CA134,026A patent/CA958314A/en not_active Expired
- 1972-02-08 FI FI341/72A patent/FI53894C/en active
- 1972-02-08 FR FR7204056A patent/FR2126760A5/fr not_active Expired
- 1972-02-09 SE SE7201498A patent/SE451098B/en unknown
- 1972-02-09 JP JP47014295A patent/JPS5247011B1/ja active Pending
- 1972-02-09 ES ES399608A patent/ES399608A1/en not_active Expired
- 1972-02-09 DK DK058072A patent/DK150170C/en not_active IP Right Cessation
- 1972-02-09 BR BR729/72A patent/BR7200729D0/en unknown
- 1972-02-09 DE DE2206103A patent/DE2206103B2/en not_active Ceased
- 1972-02-10 BE BE779209A patent/BE779209A/en not_active IP Right Cessation
-
1978
- 1978-05-11 CA CA303,100A patent/CA1040082B/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
Also Published As
Publication number | Publication date |
---|---|
GB1363565A (en) | 1974-08-14 |
DK150170C (en) | 1987-06-29 |
BR7200729D0 (en) | 1973-10-25 |
DK150170B (en) | 1986-12-22 |
DE2206103B2 (en) | 1975-10-16 |
DE2206103A1 (en) | 1972-08-24 |
FI53894C (en) | 1978-08-10 |
ES399608A1 (en) | 1974-11-16 |
SE451098B (en) | 1987-08-31 |
CH573115A5 (en) | 1976-02-27 |
NL7101728A (en) | 1972-08-14 |
BE779209A (en) | 1972-05-30 |
FI53894B (en) | 1978-05-02 |
AU3855272A (en) | 1973-08-09 |
US3791932A (en) | 1974-02-12 |
JPS5247011B1 (en) | 1977-11-29 |
CA958314A (en) | 1974-11-26 |
FR2126760A5 (en) | 1972-10-06 |
ZA72548B (en) | 1972-10-25 |
NL154600B (en) | 1977-09-15 |
AU468151B2 (en) | 1973-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1040082B (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
USRE31006E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
USRE29169E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
US4185084A (en) | Immunochemical measuring method using second antigenic substance | |
Van Weemen et al. | Immunoassay using antigen—enzyme conjugates | |
US3850752A (en) | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically | |
EP0782710B1 (en) | Method for detecting antibodies | |
US4228237A (en) | Methods for the detection and determination of ligands | |
US3839153A (en) | Process for the detection and determination of specific binding proteins and their corresponding bindable substances | |
US4343896A (en) | Method and test pack for the demonstration and determination of an antigen or antibody | |
US4434236A (en) | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue | |
CA1160566A (en) | Immunological determination method | |
US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
CH642458A5 (en) | Immunological method | |
EP0177531A1 (en) | Antibodies, manufacture and use. | |
US5459045A (en) | Reagent for immunoassay, and device using the same | |
JPH083489B2 (en) | Immunological assay | |
US4693969A (en) | Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same | |
US4288538A (en) | Test method and composition therefor | |
AU703940B2 (en) | Regenerable solid phase for carrying out specific binding reactions | |
EP0271554A1 (en) | Preparation for immunoassay and method for producing the preparation | |
JPS59210366A (en) | Manufacture of insolubilized antigen and insolubilized antibody for immunological assay | |
EP0181762B1 (en) | Method for detecting enzymatic activity using particle agglutination | |
JPH0510952A (en) | Preparation of carrier containing immobilized substance | |
US5212064A (en) | Solid phase non-separation enzyme complementation assay |